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Abstract
Genome-wide association studies (GWAS) have successfully described the roles of common genetic
variation on human diseases by analyzing large populations recruited based on a shared phenotype, but
the biological and clinical relevance of numerous genes remain incompletely described through these
‘phenotype-first’ methodologies. Much of the unexplained genetic contribution to disease risk and
variability in complex traits may belong to the very rare and private spectrum of alleles, a range
traditionally ignored by GWAS. Furthermore, the phenotype-first approach is likely to miss unexpected
phenotypic consequences of genetic variants, such as those that may not be feasible to study in a
phenotype-first approach due to rarity of the condition. The Penn Medicine BioBank, a healthcare systembased database of genotype, whole-exome sequencing, and electronic health record data, allows for an
unbiased, ‘genome-first’ approach to describing the relationships between genetic variants and human
disease traits captured in the clinical setting. Through ‘gene burden’ tests that interrogate the cumulative
effects of multiple rare and private variants in a gene that are predicted to affect gene function, this
dissertation aims to characterize the clinical manifestations of diseases and traits caused by rare,
predicted loss-of-function and predicted deleterious missense variants on an exome-wide and/or
phenome-wide scale. These analyses uncover previously unsuspected medical and biological
consequences of loss-of-function variants in multiple genes. In summary, this dissertation will investigate
the biological and clinical relevance of disease-associated genes by investigating the association of rare
coding variation found in whole-exome sequencing with phenotypes derived from the EHR.
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ABSTRACT

A GENOME-FIRST APPROACH TO INVESTIGATING THE BIOLOGICAL
AND CLINICAL RELEVANCE OF EXOME-WIDE RARE CODING VARIATION
USING ELECTRONIC HEALTH RECORD PHENOTYPES
Joseph Park
Daniel J. Rader and Marylyn D. Ritchie

Genome-wide association studies (GWAS) have successfully described the roles of
common genetic variation on human diseases by analyzing large populations recruited based on
a shared phenotype, but the biological and clinical relevance of numerous genes remain
incompletely described through these ‘phenotype-first’ methodologies. Much of the unexplained
genetic contribution to disease risk and variability in complex traits may belong to the very rare
and private spectrum of alleles, a range traditionally ignored by GWAS. Furthermore, the
phenotype-first approach is likely to miss unexpected phenotypic consequences of genetic
variants, such as those that may not be feasible to study in a phenotype-first approach due to
rarity of the condition. The Penn Medicine BioBank, a healthcare system-based database of
genotype, whole-exome sequencing, and electronic health record data, allows for an unbiased,
‘genome-first’ approach to describing the relationships between genetic variants and human
disease traits captured in the clinical setting. Through ‘gene burden’ tests that interrogate the
cumulative effects of multiple rare and private variants in a gene that are predicted to affect gene
function, this dissertation aims to characterize the clinical manifestations of diseases and traits
caused by rare, predicted loss-of-function and predicted deleterious missense variants on an
exome-wide and/or phenome-wide scale. These analyses uncover previously unsuspected
medical and biological consequences of loss-of-function variants in multiple genes. In summary,
this dissertation will investigate the biological and clinical relevance of disease-associated genes
vi

by investigating the association of rare coding variation found in whole-exome sequencing with
phenotypes derived from the EHR.
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CHAPTER 1. Introduction: Transitioning from a phenotype-first
to a genome-first era of genetic association studies

The study of the genetic basis of human disease has traditionally utilized a ‘phenotypefirst’ approach in which individuals who share a phenotypic disease trait are recruited for
genotyping or sequencing to identify gene variants that may be associated with or causal for the
phenotype of interest. Within this realm, how we have historically studied human genetic variation
can be broadly organized by minor allele frequency (MAF) into studies of common variants
versus rare variants. On one end of the allele frequency spectrum, we have studied common
(MAF > 1%) genetic variants in populations recruited based on a shared phenotype using
methods like genome-wide association studies (GWAS) to describe how these common variants
of small effect can contribute to common complex diseases, such as coronary artery disease,
type 2 diabetes, and cancer.

1-3

However, GWAS have not historically interrogated low-frequency

(0.1% < MAF ≤ 1%) and rare (MAF ≤ 0.1%) coding variation given its reliance on genotype arrays
that include common single nucleotide polymorphisms (SNPs), and more extensive exome or
genome sequencing to capture rare genetic variants had been limited to relatively small sample
sizes. On the other end of the allele frequency spectrum, rare variants, which are predicted to
have larger effect sizes, have been studied mostly in the context of Mendelian disorders such as
cystic fibrosis, familial hypercholesterolemia, and muscular dystrophy.

4,5

Identification of rare loss

of gene function variants through high-throughput DNA sequencing in such human cohorts has
allowed for the discovery of novel gene associations with various Mendelian diseases. However,
because these variants are rare, it is difficult to study their clinical implications using traditional
GWAS analysis approaches due to lack of statistical power especially when using a phenotypefirst approach, and thus the clinical implications of most rare variants are unknown.

1

To address these limitations in traditional phenotype-first approaches to genetic
association studies, this dissertation tackles the issue of how to systematically search for rare
genetic variants that confer risk for or resilience to human disease. A ‘genome-first’ approach in
which sequencing is first applied to large heterogeneous populations with subsequent
determination of the associated phenotypes is of recent interest, and transitioning to this
approach may help fill in additional puzzle pieces in the missing heritability of many human
diseases and also provide new insights into the role of many genes in human biology and
phenotypes.

6,7

To overcome the issue of statistical power while maintaining a high prevalence of

human diseases, this approach can be applied to healthcare populations with extensive electronic
8

health record (EHR) phenotype data. Furthermore, this would permit an unbiased approach to
‘phenome-wide association studies’ (PheWAS), in which a single DNA variant is associated with
various phenotypes to determine the clinical impact of specific genetic variants on the human
9

disease phenome. Importantly, a genome-first approach to PheWAS has the advantage of
testing for pleiotropy in addition to discovering new genotype-phenotype relationships.

10

Thus, if

we could combine whole-exome sequencing (WES) with EHR phenotype data, it would allow for
a genome-first approach to associating rare human genetic variants with various phenotypic data
captured natively in the documentation of clinical care.
But because rare variants are often too rare to study in a univariate association test due
to lack of statistical power,

11

genome-first approaches to genetic association tests like those

utilizing PheWAS have traditionally focused on single common variants.

12

However, gene-based

association studies that aggregate rare and private variants per gene into a ‘gene burden’ could
allow us to overcome the issue of statistical power and interrogate the association of a single
gene with various phenotypes.

13

There are various ways to collapse genetic variants into gene

burdens to conduct genetic association studies for rare variants. One apparent place to start is to
test the most damaging variants in a gene by collapsing rare predicted loss-of-function (pLOF)
variants, which include frameshift insertions/deletions, gain of stop codon (nonsense), and splice
2

site dinucleotides, into a gene burden such that each individual is scored based on the number of
rare pLOF alleles carried to ultimately compare rare pLOF carriers versus non-carriers.
Importantly, rare pLOF variants are predicted to have the largest effect on phenotypes through a
mechanism of haploinsufficiency for heterozygous carriers, whether it be via nonsense-mediated
decay or truncated proteins with altered function. Another approach is to assess predicted
deleterious missense (pDM) variants, although they may have smaller effects on phenotypes and
their directionality of effect may not always be predictable when compared to pLOF variants. For
example, one may select pDM variants for inclusion into gene burdens according to clinical
classifications of pathogenicity (e.g. ClinVar, InterVar)

14,15

and/or in silico algorithmic predictions

of probability for being damaging to the gene product (e.g. SIFT, PolyPhen2 HumDiv/HumVar,
LRT, MutationTaster, REVEL).

16-20

Yet another method for variant selection for gene burden

testing could be to select variants defined by a specific maximum minor allele frequency
threshold. Clearly, the list is not limited to these examples, and there are various additional ways
to select rare coding variants for inclusion in gene burden tests of association.

8,10,21

This dissertation entails extensive genome-first analyses that detail various ways to
collapse genetic variants into gene burdens to conduct gene-based association studies, whether
it be unbiased using a PheWAS approach or targeted to selected quantitative and/or qualitative
phenotypes (Figure 1.1). These analyses leveraged the Penn Medicine BioBank (PMBB,
University of Pennsylvania), a large academic medical biobank enriched for various human
diseases with WES data linked to EHR phenotype data, to test the performance of variant
selection methods and to conduct gene burden association tests to uncover new gene biology
and function. Importantly, because the PMBB is a healthcare population of ~60,000 individuals
with a higher prevalence of disease compared to other population-based biobanks like the UK
Biobank, there is more potential for discovery of novel gene-phenotype relationships.

22

PMBB is

also an ancestrally diverse population, with about a quarter of the population being of African
ancestry. While previous genetic association studies have typically focused on European
3

ancestry individuals, PMBB’s ancestral diversity allows us to characterize previously undescribed
genetic variants that are enriched among individuals of African ancestry.

Exploring variant selection methods and gene burdening
strategies for rare variants to conduct gene burden PheWAS
using ‘positive control’ cardiomyopathy genes

Chapter 2. A genome-first approach to
aggregating rare genetic variants in LMNA
for association with electronic health
record phenotypes

Chapter 3. A genome-first approach to rare
variants in hypertrophic cardiomyopathy
genes MYBPC3 and MYH7 in a
medical biobank

Exome-wide association analyses of rare coding variants
to discover new gene-disease relationships and reveal
new insights into human biology and disease

Chapter 4. Exome-wide evaluation of rare
coding variants using electronic health records
identifies new gene-phenotype associations

Chapter 5. Exome-wide association of rare
coding variants with hepatic fat derived from
CT imaging in a medical biobank

Figure 1.1. Flow chart summarizing each experimental dissertation chapter

This dissertation explores genome-first approaches to variant selection methods and
gene burdening strategies for rare coding variants to conduct gene burden PheWAS in PMBB.
Importantly, Chapters 2 and 3 entail application of the unbiased genome-first approach to
‘positive control’ genes with known phenotype associations which represent valuable systems for
comparison of variant selection methods and gene burdening strategies. More specifically,
Chapter 2 focuses on the gene LMNA, in which pathogenic variants are known to be highly
pleiotropic and cause several rare diseases including dilated cardiomyopathy. This chapter shows
how we found the ensemble tool REVEL

20

outperformed other in silico prediction algorithms in
4

selecting pDM variants for inclusion in the LMNA gene burden to achieve the strongest
association with the expected dilated cardiomyopathy phenotype. Subsequent follow-up PheWAS
analyses on the ideal LMNA gene burden as well as review of clinical charts revealed that
pathogenic LMNA variants are an underdiagnosed cause of cardiomyopathy and that LMNA lossof-function may be a primary cause of renal disease. Similarly, Chapter 3 focuses on the two
genes for which pathogenic variants account for up to 50% of all clinically recognized cases for
hypertrophic cardiomyopathy, namely MYBPC3 and MYH7. This chapter shows how we found
that the approach to aggregating rare variants for these two genes produced drastically different
results: pLOFs but not pDM variants in MYBPC3 were strongly associated with HCM, whereas
pDM but not pLOF variants in MYH7 were strongly associated with HCM. Importantly, this
chapter shows the importance of evaluating both pLOF and pDM variants for gene burden testing
for discovery of new gene-disease relationships and identification of new pathogenic loss-offunction variants across the human genome.
Then, in Chapters 4 and 5, the variant selection and gene burdening strategies
interrogated in Chapters 2 and 3 are applied on an exome-wide scale to conduct exome-wide
association studies for a variety of EHR-derived phenotypes in PMBB. Chapter 4 evaluates rare
pLOF variants for each individual gene on an exome-wide scale by applying gene burden
PheWAS to every adequately powered gene, essentially representing the first ‘exome-byphenome-wide association study’ in a medical biobank. In addition to verifying several ‘positive
control’ gene-phenotype associations, Chapter 4 details how this approach led to discovery of 21
novel and robustly replicated gene-phenotype relationships through interrogation of pLOF and
pDM variants in PMBB, several other medical biobanks, and the population-based UK Biobank.
Finally, Chapter 5 evaluates rare variant gene burdens as well as single low-frequency and
common coding variants on an exome-wide scale for association with hepatic fat quantifications
derived from abdominal CT scans in PMBB, representing the first exome-wide association study
for hepatic fat in a medical biobank. Importantly, Chapter 5 confirms that the approaches taken in
5

Chapters 2-4 for qualitative phenotypes can also be applied to quantitative phenotypes, verifies
‘positive control’ single variants which have previously been associated with differences in hepatic
fat or risk for non-alcoholic fatty liver disease (NAFLD), and discovers new single variants and
rare variant gene burdens associated with differences in hepatic fat.
In summary, as the genome-first approach is becoming increasingly utilized in parallel to
the traditional phenotype-first approach, and the prevalence of high-throughput sequencing in
healthcare-based biobank populations rises and subsequently identifies more rare coding
variants, this dissertation explores the value and importance of genome-first approaches to
investigating the biological and clinical relevance of exome-wide rare coding variation using EHR
phenotypes in medical biobanks.

6

CHAPTER 2. A genome-first approach to aggregating rare
genetic variants in LMNA for association with electronic health
record phenotypes

This chapter was adapted from:
Park J, Levin MG, Haggerty CM, Hartzel DN, Judy R, Kember RL, Reza N; Regeneron Genetics
Center, Ritchie MD, Owens AT, Damrauer SM, Rader DJ. A genome-first approach to
aggregating rare genetic variants in LMNA for association with electronic health record
phenotypes. Genetics in Medicine. 2020 Jan;22(1):102-111. Doi: 10.1038/s41436-019-0625-8.

2.1. Abstract
Purpose: ‘Genome-first’ approaches, in which genetic sequencing is agnostically linked to
associated phenotypes, can enhance our understanding of rare variants’ contributions to disease.
Loss-of-function variants in LMNA cause a range of rare diseases, including cardiomyopathy.
Methods: We leveraged exome sequencing from 10,996 unselected individuals in the Penn
Medicine BioBank to associate rare variants in LMNA with diverse EHR-derived phenotypes. We
used REVEL to annotate rare missense variants, clustered predicted deleterious and loss-offunction variants into a ‘gene burden’ (N=72 individuals), and performed a phenome-wide
association study (PheWAS). Major findings were replicated in DiscovEHR.
Results: The LMNA gene burden was significantly associated with primary cardiomyopathy
(p=1.78E-11) and cardiac conduction disorders (p=5.27E-07). Most patients had not been
clinically diagnosed with LMNA cardiomyopathy. We also noted an association with chronic
kidney disease (p=1.13E-06). Regression analyses on echocardiography and serum labs
revealed that LMNA variant carriers had dilated cardiomyopathy and primary renal disease.
7

Conclusion: Pathogenic LMNA variants are an underdiagnosed cause of cardiomyopathy. We
also find that LMNA loss-of-function may be a primary cause of renal disease. Finally, we show
the value of aggregating rare, annotated variants into a ‘gene burden’ and using PheWAS to
identify novel ontologies for pleiotropic human genes.

2.2. Introduction
The study of the genetic basis of human disease has traditionally utilized a ‘phenotypefirst’ approach in which persons with phenotypic disease traits are genotyped or sequenced to
identify gene variants that may be associated with or causal for disease.

4,5

A ‘genome-first’

approach in which sequencing is applied to large heterogeneous populations with subsequent
determination of the associated phenotypes is of interest.

6,7

This approach can be applied to

healthcare populations with extensive electronic health record (EHR) phenotype data, thus
permitting an unbiased approach to ‘phenome-wide association studies’ (PheWAS) to determine
the clinical impact of specific genetic variants.

8,23

In addition to identifying previously unsuspected

gene ontologies, this approach may also reveal that many patients with single-gene Mendelian
disorders are not clinically diagnosed.

24

Large-scale exome sequencing allows for the identification of rare exonic variants.
Statistical aggregation tests that interrogate the cumulative effects of multiple rare variants in a
gene (i.e. ‘gene burden’) increase the statistical power of regression analyses and enable genebased association studies to describe the implications of mutated genes in human disease. Gene
burden PheWAS in large healthcare populations could increase the potential to uncover novel
consequences of gene variants in the human disease phenome. One approach to gene burden
8

PheWAS is to focus only on predicted loss-of-function (pLOF) variants, but could lead to lack of
power due to their infrequency. To address this issue, private and very rare missense variants

8

could be added to substantially increase the number of genotypic cases. However, a major
challenge is deciding which missense variants to include in gene burden tests of association.
The unbiased genome-first approach is an ideal system for studying the effects of rare
variants in genes with known pleiotropy. Pathogenic variants in LMNA are highly pleiotropic and
cause several rare diseases including dilated cardiomyopathy, familial partial lipodystrophy type
2, and Emery-Dreifuss muscular dystrophy, among others.

25-28

We leveraged the Penn Medicine

BioBank (PMBB, University of Pennsylvania), a large academic biobank with exome sequencing
linked to EHR data, to evaluate in detail the phenotypes associated with rare pLOF and
annotated deleterious missense variants in LMNA. In addition to mining qualitative ICD-based
diagnosis codes, we interrogated EHR data for quantitative phenotypic traits via analyses of
clinical imaging and laboratory measurements. Our findings represent the first report of a
genome-first approach to examining the clinical effects of pLOF and predicted deleterious
missense (pDM) variants in LMNA.

2.3. Materials and Methods
2.3.1. Setting and study participants
All individuals recruited for the Penn Medicine BioBank (PMBB) are patients of clinical
practice sites of the University of Pennsylvania Health System. Appropriate consent was obtained
from each participant regarding storage of biological specimens, genetic sequencing, and access
to all available EHR data. The study was approved by the Institutional Review Board of the
University of Pennsylvania and complied with the principles set out in the Declaration of Helsinki.
The DiscovEHR cohort was used to replicate major findings. DiscovEHR is a
collaboration between the Geisinger Health System and Regeneron Genetics Center in which

9

exome sequencing was performed on biospecimens collected and linked to EHR data through
Geisinger’s MyCode Community Health Initiative.

29

2.3.2. Exome sequencing
This study included a subset of 11,451 individuals in PMBB who had exome sequencing.
We extracted DNA from stored buffy coats and then obtained exome sequences as generated by
the Regeneron Genetics Center (Tarrytown, NY). These sequences were mapped to GRCh37 as
previously described.

30

For subsequent phenotypic analyses, we removed samples with low

exome sequencing coverage (i.e. less than 75% of targeted bases achieving 20x coverage;
N=46), high missingness (i.e. greater than 5% of targeted bases; N=14), high heterozygosity
(N=97), dissimilar reported and genetically determined sex (N=104), genetic evidence of sample
rd

duplication (N=89), and cryptic relatedness (i.e. closer than 3 degree relatives; N=145) with
overlap among categories, leading to a total of 455 removed from our database for a total study
set of 10,996 individuals. Of note, among the 72 individuals identified as carrying one of pLOF
variants or missense variants with Rare Exome Variant Ensemble Learner (REVEL)

20

scores of at

least 0.65 who were used for the primary analyses of this work, four individuals were removed
from subsequent analyses due to low coverage (N=2), sex discordance (N=1), and being part of a
parent-child pair (N=1).
Exome sequencing in the DiscovEHR cohort was also performed by the Regeneron
Genetics Center, as previously described.

8,31

In addition to exclusions for sequence quality,

sample duplicates, and sex discordance, we excluded 31,399 individuals with closer than 3
degree relatedness, yielding a study set of 61,056 individuals.

10

rd

2.3.3. Variant annotation and selection for gene burden association testing
For both PMBB and DiscovEHR, variants were annotated using ANNOVAR

32

as

predicted loss-of-function (pLOF) or missense variants. pLOFs were defined as frameshift
insertions or deletions, gain or loss of stop codon, and disruption of canonical splice site
dinucleotides. Only variants with minor allele frequencies (MAF) ≤ 0.1% per the Genome
Aggregation Database (gnomAD) were considered for inclusion in the gene burden association
testing. Several approaches to inclusion of rare variants in the gene burden were applied,
including pLOFs only, additional ClinVar pathogenic variants, and inclusion of missense variants
that were scored deleterious by 5/5 algorithms (SIFT,
HumVar,

17

LRT,

18

16

PolyPhen2 HumDiv, Polyphen2

19

MutationTaster ). To capture additional individuals with potentially pathogenic

missense variants, we utilized an ensemble method for predicting the pathogenicity of missense
variants called REVEL to score rare missense variants in LMNA.

20

2.3.4. Clinical data collection
International Classification of Diseases Ninth Revision (ICD-9) and Tenth Revision (ICD10) diagnosis codes and procedural billing codes, medications, and clinical imaging and
laboratory measurements were extracted from the patients’ EHR. All laboratory values measured
in the outpatient setting were extracted for participants from the time of enrollment in the Biobank
until March 3, 2018; all units were converted to their respective clinical Traditional Units.
Minimum, median, and maximum measurements of each measurement were recorded per
individual. Glomerular filtration rate (GFR) estimates were calculated using the CKD-EPI
Creatinine equation, given its superiority to the MDRD equation in patient populations with normal
or mildly reduced eGFR. Inpatient and outpatient echocardiography measurements were
extracted if available for participants from January 1, 2010 until September 9, 2016; outliers for
each echocardiographic parameter (less than Q1 – 1.5*IQR or greater than Q3 + 1.5*IQR) were
11

removed. Similarly, minimum, median, and maximum values for each parameter were recorded
per patient.
For DiscovEHR, phenotypes were retrieved from Geisinger’s Phenomic-Initiative
database, which incorporates numerous sources (including the EHR) into a common data model.
Patient demographics and ICD-10 codes from inpatient and outpatient encounters were retrieved
as of November 28, 2018. ICD-9 codes were mapped to equivalent ICD-10 codes using
underlying diagnosis codes.

2.3.5. Phenome-wide association studies
A PheWAS approach was used to determine the phenotypes associated with predicted
deleterious variants in LMNA carried by individuals in PMBB.

33

ICD-10 encounter diagnoses were

mapped to ICD-9 via the Center for Medicare and Medicaid Services 2017 General Equivalency
Mappings (https://www.cms.gov/Medicare/Coding/ICD10/2017-ICD-10-CM-and-GEMs.html) and
manual curation. Phenotypes for each individual were then determined by mapping ICD-9 codes
to distinct disease entities (i.e. Phecodes) using the R package “PheWAS”.

34

Patients were

determined to have a certain Phecode if they had the corresponding ICD diagnosis on 2 or more
dates, while phenotypic controls consisted of individuals who never had the ICD code. Individuals
with an ICD diagnosis on only one date as well as individuals under control exclusion criteria
based on PheWAS phenotype mapping protocols were not considered in statistical analyses.
Each disease phenotype was tested for association with the LMNA gene burden using a
2

logistic regression model adjusted for age, age , gender, and the first ten principal components of
genetic ancestry. We used an additive genetic model to collapse predictably deleterious LMNA
variants via an extension of the fixed threshold approach.

35

Given the relatively high percentage

of individuals of African ancestry present in PMBB, PheWAS analyses were performed separately
by European and African genetic ancestry and combined with inverse variance weighted meta12

analysis. Our association analyses considered only disease phenotypes with at least 200 cases
(≥ ~1.75% prevalence in the cohort), based on a prior simulation study for power analysis of
PheWAS.

36

This led to the interrogation of 333 total phenotypes, and we used a Bonferroni

correction to adjust for multiple testing (p=0.05/333≈1.5E-04).
Replication of major PheWAS findings in DiscovEHR was performed using a logistic
2

regression model adjusted for age, age , sex, and the first four principal components of ancestry.
Dilated cardiomyopathy was defined as two or more encounter diagnoses of I42.0 (“Dilated
cardiomyopathy”), or two or more instances of I42.8 (“Other cardiomyopathies”)/I42.9
(“Cardiomyopathy, unspecified”) diagnoses and mention of “dilated” in the underlying diagnosis
code. Chronic kidney disease was defined as two or more encounter diagnoses of N18.3
(“Chronic kidney disease, stage 3 (moderate)”). For both phenotypes, patients with only one
encounter diagnosis were excluded from analysis.

2.3.6. Statistical analyses
To compare available echocardiographic and serum laboratory measurements between
carriers of predicted deleterious LMNA variants and genotypic controls, we used a nonparametric
statistical model to compare each clinical measurement between the two groups using the
Wilcoxon rank-sum test (i.e. Mann-Whitney U test). Additionally, comparisons were made using
2

robust linear regression, adjusted for age, age , gender, and the first ten principal components of
genetic ancestry, in both the overall population and individuals of European ancestry alone.
Furthermore, 95% confidence intervals and p-values were corrected by bootstrapping with 1000
replicates via the adjusted percentile method. All statistical analyses, including PheWAS, were
completed using R version 3.3.1 or version 3.5 (Vienna, Austria).
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2.4. Results
2.4.1. Phenome-wide association studies for gene burden of deleterious variants in LMNA
Among 10,996 individuals in PMBB with exome sequencing included in this study, we
identified a total of 11 individuals carrying one of nine different pLOF variants (including five
frameshift insertions/deletions, one gain of stop codon, and three variants disrupting canonical
splice site dinucleotides) in LMNA (Appendix A, Table S1). All 11 individuals carrying pLOF
variants were cases for Phecodes “primary/intrinsic cardiomyopathy,” “cardiac conduction
disorders,” or both, confirming that heterozygous pLOF variants in LMNA have a high penetrance
for cardiomyopathy. Interestingly, only four of these 11 individuals had received clinical genetic
testing to confirm their laminopathies.
A PheWAS on the 11 carriers for pLOFs alone showed a signal for cardiomyopathy
(Appendix A, Figure S1) but had insufficient power; furthermore, most known pathogenic LMNA
variants are missense variants. Therefore, we identified 167 individuals with one of 88 rare (MAF
≤ 0.1% in gnomAD) missense variants in LMNA (Appendix A, Table S1). We aggregated pLOF
variants and missense variants annotated as “Pathogenic” in ClinVar (N=9 different variants, 20
carriers) and performed PheWAS (N=33 carriers), resulting in a stronger signal for
cardiomyopathy that was significant (Appendix A, Figure S2). Given that many of the rare LMNA
variants were of unknown pathogenicity, we combined missense variants predicted to be
deleterious by a consensus of 5/5 algorithms (SIFT,
LRT,

18

16

PolyPhen2 HumDiv, Polyphen2 HumVar,

17

19

MutationTaster ), one of the standard approaches for combining pLOF variants with
8

computationally predicted pathogenic missense variants (N=14 different variants, 24 carriers;
Appendix A, Table S1), in a gene burden PheWAS (N=35 carriers; Figure 2.1.A). The signal for
cardiomyopathy diagnoses was even stronger, additionally identifying related Phecodes such as
“first degree AV block”, “sinoatrial node dysfunction”, and “congestive heart failure”.
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Figure 2.1. Phenome-wide association studies (PheWAS) of predicted deleterious LMNA variants.
Gene burden tests of association for predicted loss-of-function (pLOF) variants and predicted deleterious
missense (pDM) variants in LMNA. (A) Gene burden PheWAS of pLOF variants (N=11 carriers) and
missense variants predicted to be deleterious by 5/5 algorithms (SIFT, PolyPhen2 HumDiv, Polyphen2
HumVar, MutationTaster, and LRT; N=24). The blue line represents a p-value of 0.05, and the red line
represents the Bonferroni corrected significance threshold to adjust for multiple testing (p=0.05/333). (B) Plot
of p-value for gene burden association with “primary/intrinsic cardiomyopathy” using pLOF variants and
missense variants predicted to be deleterious per various REVEL cutoff scores as well as 5/5 algorithms.
Each point is labeled with the number of exome-sequenced individuals who are carriers for missense
variants in each threshold category without using a minor allele frequency threshold. (C) Venn diagram of
number of exome-sequenced carriers for missense variants predicted to be deleterious by 5/5 algorithms
and/or with a REVEL score ≥ 0.65. (D) Gene burden PheWAS of pLOF variants (N=11) and missense
variants with REVEL scores of at least 0.65 (N=61). The blue line represents a p-value of 0.05, and the red
line represents the Bonferroni corrected significance threshold to adjust for multiple testing (p=0.05/333).
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However, we noted that there were a substantial number of carriers for rare missense
variants in LMNA that did not meet the 5/5 criteria who were diagnosed with “primary/intrinsic
cardiomyopathy” (Appendix A, Table S1), suggesting that this algorithmic filter was too stringent.
To capture more individuals with pathogenic missense variants, we utilized REVEL, which has
been reported to more accurately distinguish pathogenic from neutral missense variants,
particularly those with MAFs less than 0.5%, compared to other predictive methods.

20

Analysis of

variance on ClinVar-annotated variants showed that REVEL scores correlate with clinical
pathogenicity (Appendix A, Table S2). While a threshold of 0.5 has been suggested,

20

we

experimented with REVEL score thresholds in bins of 0.05 to evaluate the optimal score cutoff for
capturing the most robust association with cardiomyopathy as a positive control (Figure 2.1.B). Of
note, all REVEL cutoff scores of at least 0.5 performed better in identifying association with
“primary/intrinsic cardiomyopathy” compared to the usage of 5/5 algorithms.
We chose a REVEL cutoff score of 0.65 given its optimal p-value for association with
“primary/intrinsic cardiomyopathy” (Figure 2.1.B) while maintaining relatively high numbers of
carriers for predictably deleterious LMNA variants. This cutpoint included 19 of the 24 carriers (11
of the 14 variants) that met the 5/5 criteria, but also included 42 additional carriers (21 variants)
that did not meet the 5/5 criteria (Figure 2.1.C). PheWAS of the LMNA gene burden of pLOF
variants plus missense variants with REVEL scores of at least 0.65 (N=72 carriers) revealed a
much more robust signal for cardiomyopathy and related phenotypes (Figure 2.1.D, Table 2.1).
Of note, the signal was more statistically robust compared to other recently developed ensemble
methods for predicting pathogenicity such as VEST3
(Appendix A, Figure S4), and CADD

40

37,38

(Appendix A, Figure S3), M-CAP

39

(Appendix A, Figure S5). Furthermore, we addressed

potential issues of small sample sizes by using Firth’s penalized likelihood approach, and found
that beta and p-value estimates were consistent with exact logistic regression (Appendix A, Table
S3). Importantly, only six of the 35 individuals with a rare deleterious variant in LMNA and a
Phecode diagnosis of “primary/intrinsic cardiomyopathy” had been molecularly diagnosed with a
16

LMNA variant (Table 2.1), indicating that LMNA cardiomyopathy is substantially underdiagnosed.
Furthermore, 15 missense variants with REVEL scores > 0.5 that are annotated as variants of
uncertain significance or having conflicting interpretations of pathogenicity had at least one carrier
with a Phecode diagnosis of “primary/intrinsic cardiomyopathy” and/or “cardiac conduction
disorder” (Appendix A, Table S1).

Basic demographics

LMNA

N

+/-

LMNA

+/+

OR

p-value

68

10928

-

-

38 (55.9)

6489 (59.4)

-

0.625

63.4

67.9

-

0.021

AFR, N (%)

12 (17.6)

2191 (20.0)

-

-

AMR, N (%)

4 (5.9)

303 (2.8)

-

-

Male, N (%)
Median Age (at biobank entry), yr
Race

EAS, N (%)

0 (0)

79 (0.7)

-

-

EUR, N (%)

51 (75.0)

8208 (75.1)

-

-

SAS, N (%)

1 (1.5)

114 (1.0)

-

-

Diabetes Mellitus, N (%)

26 (38.2)

3508 (32.1)

1.31

0.298

Hypertension, N (%)

51 (75.0)

7957 (72.8)

1.12

0.785

Coronary Artery Disease, N (%)

32 (47.1)

4765 (43.6)

1.15

0.624

Myocardial Infarction, N (%)

14 (20.6)

2214 (20.3)

0.98

0.881

Heart Failure, N (%)

41 (60.3)

4159 (38.1)

2.47

2.40E-04

Dilated Cardiomyopathy, N (%)

19 (27.9)

610 (5.6)

8.57

4.48E-09

Heart Transplant, N (%)

14 (20.6)

379 (3.5)

7.21

1.00E-07

Primary/intrinsic cardiomyopathy, N (%)

35 (58.3)

1608 (18.3)

6.37

1.78E-11

Cardiac conduction disorders, N (%)

42 (82.4)

2594 (44.4)

7.13

5.27E-07

Atrial fibrillation, N (%)

39 (81.3)

3352 (50.8)

5.64

1.42E-05

Atrioventricular (AV) block, N (%)

15 (62.5)

565 (14.8)

14.02

1.22E-08

Sinoatrial node dysfunction (bradycardia), N (%)

15 (62.5)

544 (14.4)

13.67

4.89E-08

Paroxysmal ventricular tachycardia, N (%)

27 (75.0)

1318 (28.9)

7.59

1.09E-06

Cardiac pacemaker/device in situ, N (%)

36 (80.0)

1849 (36.3)

8.53

7.90E-08

Cardiac defibrillator in situ, N (%)

28 (75.7)

1263 (28.0)

9.20

6.65E-08

Congestive heart failure; nonhypertensive, N
(%)
Heart failure with reduced EF, N (%)

40 (64.5)

3504 (42.1)

3.38

1.29E-05

20 (47.6)

1415 (22.7)

3.82

8.23E-05

Heart transplant/surgery, N (%)

15 (40.5)

472 (8.9)

6.67

1.27E-07

Chronic Kidney Disease, Stage III, N (%)

15 (30.6)

746 (10.3)

4.91

1.13E-06

Clinical Cardiometabolic Diagnoses

PheCodes
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Table 2.1. Demographics, clinical characteristics, and significant cardiovascular Phecode
associations for individuals in PMBB carrying a predicted deleterious LMNA variant.
Top and middle: Basic demographic characteristics (top) and cardiometabolic diagnoses (middle) for 68 of
72 heterozygous carriers of predicted loss-of-function (pLOF) variants (N=11) and missense variants with
+/-

REVEL scores of at least 0.65 (N=61) (represented as LMNA ) compared to non-carriers in the overall
+/+

PMBB population (represented as LMNA ). Each characteristic is labeled with count data in the LMNA
carrier population and the rest of PMBB, as well as p-values for two-tailed Fisher’s exact tests. Of note, four
of 72 carriers were not included due to additional genotypic quality-check measures (see Methods). Bottom:
representative cardiovascular and renal Phecodes identified by gene burden PheWAS for predicted
deleterious exonic variants in LMNA (predicted loss-of-function variants and missense variants with a
REVEL score of at least 0.65, N=72). Patients were determined to have a certain Phecode if they had the
corresponding ICD diagnosis on 2 or more dates, while phenotypic controls consisted of individuals who
never had the ICD code. Individuals with an ICD diagnosis on only one date as well as individuals under
control exclusion criteria based on PheWAS phenotype mapping protocols were not considered in statistical
analyses. Each phenotype is labeled with count and proportion data in the LMNA carrier population and the
rest of PMBB, as well as odds-ratios and p-values attributable to LMNA carrier status via logistic regression
2

adjusted for age, age , gender, and the first ten principal components of genetic ancestry. AFR-African,
AMR-Mixed American, EAS-East Asian, EUR-European, SAS-South Asian

Given the variety of cardiovascular traits that were highly significant in the REVELinformed gene burden PheWAS for LMNA, we addressed whether these are independent signals.
After running association analyses among all individuals with a phenotype of “primary/intrinsic
cardiomyopathy”, we found that the entire spectrum of cardiovascular PheWAS signals
disappeared, suggesting that the other cardiac phenotypes were secondary to primary
cardiomyopathy in carriers of the deleterious LMNA variants (Appendix A, Figure S6).
In addition to cardiac disease phenotypes, our REVEL-informed LMNA gene burden
PheWAS also identified phenome-wide significant disease phenotypes that are not typically
defined as laminopathies, including “chronic kidney disease, stage III” (p=1.13E-06; Figure 2.1.D,
Table 2.1). The relative persistence of the association signal for “chronic kidney disease, stage
III” (p=1.33E-03) when controlling for primary cardiomyopathy suggests an independent
pathophysiological mechanism for renal failure in the context of loss of function in LMNA
(Appendix A, Figure S6).
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We replicated these observations in the DiscovEHR cohort using the same approach
(pLOFs plus REVEL score ≥ 0.65; Appendix A, Table S4A). There was a significant association
between LMNA gene burden and dilated cardiomyopathy (OR: 4.2 [95% CI: 1.3 – 10.0], p =
0.005; Table S4B). Furthermore, the association of LMNA gene burden with chronic kidney
disease was also replicated (OR: 1.6 [95% CI: 1.1 – 2.5], p = 0.02; Appendix A, Table S4B).

2.4.2. Association of LMNA gene burden with cardiovascular imaging and clinical laboratory data
To build upon the PheWAS findings, we took a deeper dive into the cardiovascular
imaging and laboratory EHR data. First, we analyzed the cardiac structures of these individuals
by interrogating available echocardiography data. By doing so, we also aimed to better define the
Phecode “primary/intrinsic cardiomyopathy,” which does not differentiate between the different
types of primary cardiomyopathy. Carriers of rare deleterious LMNA variants had heart
morphology consistent with dilated cardiomyopathy when compared to the rest of the PMBB
population with echo data available (Table 2.2; Appendix A, Table S5A-B). More specifically,
carriers had significantly increased left atrial volume indices, decreased left ventricular ejection
fractions, decreased left ventricular outflow tract velocity time integrals, and increased mitral E/A
ratios as an indication for weak atrial contraction.
We also conducted similar quantitative analyses for select clinical laboratory
measurements. Carriers of predicted deleterious LMNA variants had significantly elevated alanine
transaminase (ALT) and aspartate transaminase (AST) levels when compared to individuals not
carrying a predicted deleterious LMNA variant (Table 2.3; Appendix A, Table S6A). In the overall
population, carrier status was significantly associated with increased total cholesterol levels
(Table 2.3; Appendix A, Table S6A-B). Furthermore, maximum blood triglyceride levels trended to
be elevated among carriers (p=0.0559; Table 2.3). These laboratory features are consistent with
subclinical features of partial lipodystrophy, such as fatty liver and dyslipidemia. While only two of
19

the 72 carriers of predicted deleterious variants had an ICD diagnosis of “lipodystrophy,” there
were 44 carriers with a phenotype of “hyperlipidemia,” 20 carriers with a diagnosis of “type 2
diabetes”, and eight with “secondary diabetes mellitus”. Comprehensive investigation of physical
exam notes written by healthcare providers for individuals with these related metabolic
phenotypes showed no mention of loss of subcutaneous fat from the extremities, trunk, or gluteal
region, which is the classic presentation specific to partial lipodystrophy type 2.

Echo parameter
Left atrial volume index,

LMNA

Median (IQR)

36.982 (27.329, 49.802)

20

2648

4.010 (3.563, 4.637)

3.490 (2.970, 4.290)

31

4643

5.282 (4.792, 5.792)

4.980 (4.420, 5.591)

32

4696

45.00 (40.00, 55.00)

55.00 (40.00, 65.00)

33

5506

17.070 (14.200, 21.200)

19.100 (15.300, 23.175)

28

3846

1.753 (1.413, 2.541)

1.312 (0.942, 1.901)

26

4529

fraction (LVEF), minimum
Left ventricular outflow tract

+/+

52.592 (37.491, 60.381)

diameter PLAX, maximum (cm)
Left ventricular ejection

LMNA

N

diameter PLAX, maximum (cm)
Left ventricular diastolic

Median (IQR)
N

maximum
Left ventricular end systolic

+/-

(LVOT) velocity time integral,

ß

p

11.582

0.00649

0.512

0.0159

0.188

0.235

-7.501

0.0162

-2.801

0.0114

0.517

0.0124

minimum (cm)
Mitral E/A ratio, maximum

Table 2.2. Cardiac architecture for carriers of presumed deleterious variants in LMNA is consistent
with dilated cardiomyopathy. Comparison of representative echocardiography parameters for cardiac size
and functionality between heterozygous carriers of predicted loss-of-function variants and missense variants
+/-

with REVEL scores of at least 0.65 (represented as LMNA ), and individuals in PMBB not carrying one of
+/+

presumed deleterious variants with echocardiographic data available (represented as LMNA ). Data is
st

rd

represented as median, respective 1 and 3 quartiles, the number of individuals from each population with
available measurement data, and corresponding beta and p-value attributable to LMNA carrier status via
2

robust linear regression adjusted for age, age , gender, and the first ten principal components of genetic
ancestry. 95% confidence intervals and p-values were corrected by bootstrapping with 1000 samples.
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Lab parameter

LMNA

+/-

Median (IQR)

LMNA

+/+

Median (IQR)

N

N

ALT, maximum (U/L)

58.50 (32.25, 143.50)

36.00 (23.00, 62.00)

50

8459

AST, maximum (U/L)

53.50 (35.50, 109.50)

35.00 (25.00, 63.00)

50

8392

208.00 (180.00, 248.00)

196.00 (162.00, 231.00)

43

6037

116.00 (90.50, 143.50)

114.00 (88.00, 145.00)

43

5982

41.00 (29.00, 50.75)

39.00 (31.00, 50.00)

Total cholesterol, maximum (mg/dL)
LDL, maximum (mg/dL)
HDL, minimum (mg/dL)
Triglycerides, maximum (mg/dL)
Creatine kinase, maximum
2

eGFR, minimum (mL/min/1.73 m )
Albumin (serum), minimum (g/dL)
Urine protein, maximum (mg/dL)

42

5978

185.00 (100.50, 319.00)

149.00 (102.00, 224.00)

43

6189

133.50 (85.00, 196.50)

113.00 (71.00, 183.00)

6

1512

38.26 (18.26, 54.64)

56.94 (32.52, 79.05)

53

8238

3.00 (2.40, 3.70)

3.50 (2.90, 3.90)

50

8049

41.00 (20.00, 262.50)

22.00 (9.00, 85.00)

8

801

p
1.13E-04
1.48E-04
0.0259
0.998
0.693
0.0559
0.541
5.20E-05
4.34E-03
0.162

Table 2.3. Clinical laboratory measurements for carriers of presumed deleterious variants in LMNA is
consistent with subclinical features of partial lipodystrophy and renal disease. Unadjusted
comparison via Wilcoxon rank sum test of representative clinical laboratory parameters between
heterozygous carriers of predicted loss-of-function variants and missense variants with REVEL scores of at
+/-

least 0.65 (represented as LMNA ), and individuals in PMBB not carrying one of presumed deleterious
+/+

variants with serum laboratory data available (represented as LMNA ). Data is represented as median,
st

rd

respective 1 and 3 quartiles, the number of individuals from each population with available measurement
data, and corresponding p-value for Wilcoxon rank sum test.

Finally, regarding the identification of “chronic kidney disease, stage III” from our REVELinformed gene burden PheWAS, we compared quantitative markers of renal disease between
carriers of predicted deleterious LMNA variants and non-carriers in PMBB. We found that carrier
status was associated with significantly decreased eGFR and serum albumin levels (Table 2.3;
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Appendix A, Table S6A-B). Furthermore, eGFR was still significantly decreased among carriers of
predicted deleterious LMNA variants after adjusting for lifetime diagnosis of both congestive heart
failure and diabetes mellitus, as well as adjusting for each diagnosis separately (Table 2.4).
Additionally, serum albumin was also significantly decreased for carriers of predicted deleterious
LMNA variants after adjusting for both heart failure and diabetes mellitus lifetime diagnoses
(Table 2.4).

Lab parameter

ß

p

eGFR, minimum (mL/min/1.73 m )

2

-9.633

0.0149

Albumin (serum), minimum (g/dL)

-0.234

0.0842

eGFR, minimum (mL/min/1.73 m )

-16.121

4.59E-05

Albumin (serum), minimum (g/dL)

-0.399

5.65E-04

eGFR, minimum (mL/min/1.73 m )

-10.648

0.00554

Albumin (serum), minimum (g/dL)

-0.264

0.0283

Adjusted for Heart Failure

Adjusted for Diabetes Mellitus
2

Adjusted for HF + DM
2

Table 2.4. Renal clinical laboratory measurements for carriers of presumed deleterious variants in
LMNA are consistent with primary renal disease. Comparison of estimated glomerular filtration rate
(eGFR) and serum albumin between heterozygous carriers of predicted loss-of-function variants and
missense variants with REVEL scores of at least 0.65, and individuals in PMBB not carrying one of
presumed deleterious variants with serum laboratory data available, adjusted for lifetime congestive heart
failure diagnosis (top), diabetes mellitus diagnosis (middle), and lifetime diagnoses of both heart failure and
diabetes mellitus (bottom). Data is represented as beta and p-value attributable to LMNA carrier status via
robust linear regression adjusted for lifetime diagnosis of heart failure and/or diabetes mellitus as well as the
first ten principal components of genetic ancestry. 95% confidence intervals and p-values were corrected by
2

bootstrapping with 1000 samples. eGFR not adjusted for age, age , and gender given the dependence of
2

eGFR on age and gender per the CKD-EPI equation. Serum albumin additionally adjusted for age and age .
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2.5. Discussion
While exome-wide interrogation of patients with shared phenotypic traits has been
successful in identifying many new genetic variants associated with rare human disease, proving
causality of disease due to pathogenic genetic variants in humans in vivo remains enigmatic.

41,42

We attempt to address the limitations of traditional phenotype-first approaches through this study,
which represents a genome-first approach to analyzing the clinical manifestations of predicted
deleterious variants in LMNA by fully utilizing available EHR data. Our study serves as an
example of a genome-first approach for studying the medical consequences of rare pLOF and
deleterious missense genetic variants in specific genes within the context of large healthcare
biobanks linked to extensive EHR phenotypic data.
An important area of research in precision medicine initiatives is to create a platform by
which healthcare providers can make accurate diagnoses based on a wide variety of
personalized health data, including individuals’ genetic information. However, current genetic
panels offered at most healthcare institutions cover only a small portion of genetic variants
implicated in rare human diseases.

43

We suggest that the pipeline for interpretation of variants in

LMNA identified via clinical genetic testing should be updated, as indicated by the number of
variants of uncertain significance (VUS) identified in PMBB that we suggest may be pathogenic
given the combination of their association with cardiomyopathy and/or arrhythmia and their
predicted deleteriousness. Additionally, we found that important molecular diagnoses were
missed, as many carriers for predicted deleterious variants in LMNA with dilated cardiomyopathy
had not been sequenced for LMNA. In our analysis of PMBB, 35 individuals with a diagnosis of
“primary/intrinsic cardiomyopathy” had a rare deleterious variant in LMNA and only six had been
previously tested and molecularly diagnosed with a LMNA variant, suggesting that there is a lack
of genetic testing for laminopathies in patients with cardiomyopathy of unknown etiology.
Currently, LMNA genetic testing is not routinely offered to all patients with dilated cardiomyopathy
unless a genetic cause is suspected to underlie dilated cardiomyopathy as a primary condition.
23
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46

Furthermore, all six individuals who received testing were identified as carriers for known

pathogenic variants, suggesting that some carriers of potentially pathogenic variants annotated
as VUS as well as novel variants would not have been identified even if offered genetic testing in
the clinic. Similarly, familial partial lipodystrophy due to a pathogenic LMNA variant is also likely
underdiagnosed.
Although there are no current therapies specific to LMNA cardiomyopathy, there is
benefit to making the molecular diagnosis with regard to providing an etiology for the
cardiomyopathy, predicting clinical course and complications, and testing other family members
at risk. More effective molecular diagnoses can lead to change in medical management for these
individuals who are at high risk for arrhythmic sudden cardiac death.

47,48

In the clinical setting,

dilated cardiomyopathy patients with confirmed pathogenic LMNA variants are often referred for
electrophysiologic risk stratification earlier than other patients with non-genetic dilated
cardiomyopathy. Thus, while evaluation of the contribution of individual variants remains clinically
challenging and a definitive classification of pathogenicity for each presumed deleterious variant
is hard to predict, our analyses suggest that earlier identification of laminopathies through an
improved framework promoting genetic testing in the clinical setting using a comprehensive and
updated variant panel is warranted to provide earlier, preventive treatments.
Additionally, the increased number of specific pathogenic variants in LMNA identified
through this genome-first approach will provide greater insight into LMNA structure-function.
Interestingly, 19 of 29 known ClinVar-annotated pathogenic missense variants cause a deviation
from arginine in various locations of the LMNA protein product, highlighting a potential importance
of the positively-charged arginine in the LMNA protein structure, consistent with previous studies
identifying arginine in many splicing binding sites for generating prelamin A and lamin C.

49

Notably, among novel missense variants discovered in this study, 8 of 18 variants with REVEL
scores of at least 0.65 cause deviations from arginine, consistent with the prevalence of these
changes in known clinically pathogenic missense variants.
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This approach to inclusion of REVEL-annotated likely deleterious missense variants in a
gene burden has the advantage of increasing the power for gene burden PheWAS analyses that
can identify novel gene ontologies, as seen by the identification of advanced renal disease in the
context of loss of function in LMNA. While renal abnormalities are possible direct clinical sequelae
related to heart failure and diabetes mellitus, pathophysiological mechanisms for renal failure due
to pathogenic LMNA variants through primary, non-cardiorenal processes have recently been
suggested.

50,51

We report impaired renal function and hypoalbuminemia in the context of loss of

function in LMNA, even after adjusting for both a lifetime diagnosis of congestive heart failure and
diabetes mellitus, suggesting a pathophysiology for renal failure due to a proteinuric, primary
nephrotic clinical picture that may be confounded by, yet independent of, the pathophysiology of
heart failure in dilated cardiomyopathy and the overlap with diabetes in partial lipodystrophy. Our
results suggest a clinical or subclinical nephrotic phenotype due to loss-of-function variants in
LMNA that may have been further masked by comorbid cardiac and metabolic disease traits,
calling for follow-up studies interrogating primary renal disease as a potential novel laminopathy.
In conclusion, we used an approach to include pLOFs and REVEL-annotated deleterious
missense variants in LMNA in a gene burden to show by PheWAS, using a relatively small
number of carriers, significant associations with primary dilated cardiomyopathy, laboratory
values consistent with partial lipodystrophy, and a novel finding of chronic kidney disease. We
demonstrate the importance of deeply interrogating quantitative data in the EHR to uncover
important clinical and subclinical information relevant to other rare laminopathies implicated by
deleterious LMNA variants. Our approach suggests an expanded role for clinical genetic testing
for patients who present with primary dilated cardiomyopathy or early pathophysiologic signs like
conduction defects. Importantly, our study also lays a methodological framework by which future
studies can uncover novel gene-disease relationships and identify novel pathogenic loss-offunction variants across the human genome through genome-first analyses of large,
heterogeneous healthcare-based populations.
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CHAPTER 3. A genome-first approach to rare variants in
hypertrophic cardiomyopathy genes MYBPC3 and MYH7 in a
medical biobank

This thesis chapter was adapted from:
Park J, Packard EA, Levin MG, Judy RL, Regeneron Genetics Center, Damrauer SM, Day SM,
Ritchie MD, Rader DJ. A genome-first approach to rare variants in hypertrophic cardiomyopathy
genes MYBPC3 and MYH7 in a medical biobank. medRxiv. 2021.05.26.21257880. doi:
10.1101/2021.05.26.21257880

3.1. Abstract
‘Genome-first’ approaches to analyzing rare variants can reveal new insights into human biology
and disease. Because pathogenic variants are often rare, new discovery requires aggregating
rare coding variants into ‘gene burdens’ for sufficient power. However, a major challenge is
deciding which variants to include in gene burden tests. Pathogenic variants in MYBPC3 and
MYH7 are well-known causes of hypertrophic cardiomyopathy (HCM), and focusing on these
‘positive control’ genes in a genome-first approach could help inform variant selection methods
and gene burdening strategies for other genes and diseases. Integrating exome sequences with
electronic health records among 41,759 participants in the Penn Medicine BioBank, we evaluated
the performance of aggregating predicted loss-of-function (pLOF) and/or predicted deleterious
missense (pDM) variants in MYBPC3 and MYH7 for gene burden phenome-wide association
studies (PheWAS). The approach to grouping rare variants for these two genes produced very
different results: pLOFs but not pDM variants in MYBPC3 were strongly associated with HCM,
whereas the opposite was true for MYH7. Detailed review of clinical charts revealed that only
26

38.5% of patients with HCM diagnoses carrying an HCM-associated variant in MYBPC3 or MYH7
had a clinical genetic test result. Additionally, 26.7% of MYBPC3 pLOF carriers without HCM
diagnoses had clear evidence of left atrial enlargement and/or septal/LV hypertrophy on
echocardiography. Our study shows the importance of evaluating both pLOF and pDM variants
for gene burden testing in future studies to uncover novel gene-disease relationships and identify
new pathogenic loss-of-function variants across the human genome through genome-first
analyses of healthcare-based populations.

3.2. Introduction
‘Genome-first’ approaches, in which genetic variants of interest are first identified and
then analyzed for association with phenotypes, can be used to inform the genetic basis of human
6

disease and reveal new insights into gene function and human biology. Particularly when applied
to medical biobanks consisting of healthcare populations with DNA sequencing data linked to
extensive electronic health record (EHR) phenotype data, genome-first approaches allow for
agnostic phenome-wide association studies (PheWAS) to determine the clinical impact of specific
genetic variants.

8,9

With the rising use of large-scale whole-exome sequencing (WES) and

identification of many rare coding variants predicted to impact protein structure or function,
studies are increasingly interrogating the cumulative effect of multiple rare variants in a gene (i.e.
‘gene burden’) to increase the statistical power of regression analyses and enable gene-based
association studies to describe the implications of mutated genes in human disease.

13

We have previously shown that gene burden PheWAS applied to large healthcare
populations has the potential to uncover novel consequences of rare coding variants in the
human disease phenome.

22

One approach to gene burden PheWAS is to focus only on predicted

loss-of-function (pLOF) variants, but this could lead to lack of power due to their infrequency.
Additional coding variation could be added to substantially increase the number of effect alleles,
27

but a major challenge is deciding which variants to include in gene burden tests of association.
Furthermore, there are many in silico algorithms that can predict the probability that a variant may
have a deleterious effect on its gene product as well as various filters that can be applied for
variant selection based on variant type and frequency, but very little large-scale functional data
that can be used to annotate missense variants.
Application of the unbiased genome-first approach to ‘positive control’ genes with known
phenotype associations represents a valuable system for comparison of variant selection
methods and gene burdening strategies, as we previously showed for the gene LMNA and its
association with dilated cardiomyopathy.

10

Pathogenic variants in MYBPC3 and MYH7 are known

to cause hypertrophic cardiomyopathy (HCM) and together account for up to 50% of all clinically
recognized HCM cases and at least 75% of HCM cases for which a pathogenic variant is
identified.

52

We leveraged the Penn Medicine BioBank (PMBB, University of Pennsylvania), a

large academic medical biobank with WES linked to EHR data, to evaluate in detail the
performance of methods for aggregating pLOF and/or annotated predicted deleterious missense
(pDM) variants in MYBPC3 and MYH7 for gene burden association studies. Additionally, we
followed up on our genome-first approach with review of EHR charts to describe the clinical
characteristics of variant carriers identified through this gene burden study.

3.3. Materials and Methods
3.3.1. Setting and study participants
All individuals recruited for the Penn Medicine BioBank (PMBB) are patients of clinical
practice sites of the University of Pennsylvania Health System. Appropriate consent was obtained
from each participant regarding storage of biological specimens, genetic sequencing, and access
to all available EHR data. This study was approved by the Institutional Review Board of the
University of Pennsylvania and complied with the principles set out in the Declaration of Helsinki.
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3.3.2. Whole-exome sequencing
This study included a subset of 43,731 individuals in the PMBB who had undergone
whole-exome sequencing. We extracted DNA from stored buffy coats and then mapped exome
sequences as generated by the Regeneron Genetics Center (Tarrytown, NY) to GRCh38 as
previously described.

10

Samples with low exome sequencing coverage, high missingness (i.e.

greater than 5% of targeted bases), dissimilar reported and genetically determined sex, and
genetic evidence of sample duplication were not included in this subset.

10,22

For subsequent

st

nd

phenotypic association analyses, we removed samples with evidence of 1 and 2 -degree
relatedness, leading to a total of sample size of 41,759 for analysis.

3.3.3. Variant annotation and selection for gene burden association testing
For PMBB, variants were annotated using ANNOVAR

32

as pLOF or missense variants.

pLOFs were defined as frameshift insertions or deletions, gain of stop codon, and disruption of
canonical splice site dinucleotides. For splicing variants, we removed those with SpliceAI scores
53

< 0.2 for loss or gain of acceptor or donor site.

Several approaches to inclusion of rare variants

in the gene burden were applied, including pLOFs only, additional ClinVar pathogenic variants,
and inclusion of predicted deleterious missense (pDM) variants that were scored deleterious by
16

17

19

4/4 algorithms (SIFT , PolyPhen2 HumDiv, Polyphen2 HumVar , MutationTaster ). To capture
additional individuals with potentially pathogenic missense variants, we utilized an ensemble
method for predicting the pathogenicity of missense variants called REVEL

20

to score rare

missense variants in MYBPC3 and MYH7. Finally, we overlapped a list of all 19 expertadjudicated pathogenic missense variants in MYBPC3 from the SHaRe Database to identify highconfidence pathogenic missense variants in PMBB.

29
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3.3.4. Clinical data collection
All International Classification of Diseases Ninth Revision (ICD-9) and Tenth Revision
(ICD-10) diagnosis codes, clinical imaging and laboratory measurements were extracted from the
patients’ EHR. All ICD diagnosis codes and outpatient laboratory measurements available up to
July 2020 were extracted for PMBB participants. Inpatient and outpatient echocardiography
measurements were extracted if available for participants from September 2005 until November
2018. Outliers for each echocardiographic parameter (values >10 median absolute deviations
from the median) were removed. Minimum, median, and maximum measurements of each
quantitative trait were recorded per individual.

3.3.5. Phenome-wide association studies
A PheWAS approach was used to determine the phenotypes associated with predicted
33

deleterious variants in MYBPC3 or MYH7 carried by individuals in PMBB . ICD-10 encounter
diagnoses were mapped to ICD-9 via the Center for Medicare and Medicaid Services 2017
General Equivalency Mappings (https://www.cms.gov/Medicare/Coding/ICD10/2017-ICD-10-CMand-GEMs.html) and manual curation. Phenotypes for each individual were then determined by
mapping ICD-9 codes to distinct disease entities (i.e. Phecodes) using the R package
34

“PheWAS” . Patients were determined to be a case for a certain Phecode if they had the
corresponding ICD diagnosis on 2 or more dates, while controls consisted of individuals who
never had the ICD code. Individuals with an ICD diagnosis on only one date as well as individuals
meeting control exclusion criteria based on default PheWAS phenotype mapping protocols were
not considered in statistical analyses.
Each disease phenotype was tested for association with a gene burden of pLOF and/or
pDM variants using a logistic regression model adjusted for age, sex, and the first ten principal
components of genetic ancestry. We used an additive genetic model to aggregate variants into
30

gene burdens as previously described.

22

PheWAS analyses were performed separately by

African and European genetic ancestry and then combined with inverse variance weighted metaanalysis. Our association analyses considered only disease phenotypes with at least 20 cases
based on a prior simulation study for power analysis of rare variant gene burden PheWAS.

22

This

led to the interrogation of 1396 total Phecodes, and we used a Bonferroni correction to adjust for
multiple testing (p=0.05/1396=3.58E-05).

3.3.6. Statistical analyses
We also created a single HCM phenotype by combining Phecodes “Hypertrophic
obstructive cardiomyopathy” and “Other hypertrophic cardiomyopathy” for association with
various gene burdens in conjunction with PheWAS, using a logistic regression model adjusted for
age, sex, and the first ten principal components of genetic ancestry. These HCM-specific
analyses were performed separately by African and European genetic ancestry and combined
with inverse variance weighted meta-analysis. Additionally, to compare available
echocardiographic and serum laboratory measurements between carriers of predicted deleterious
variants and genotypic controls, we used linear regression adjusted for age, sex, and the first ten
principal components of genetic ancestry. These analyses were performed separately by African
and European genetic ancestry and combined with inverse variance weighted meta-analysis. For
echocardiographic comparison of MYBPC3 pLOF and pathogenic missense variant carriers
versus controls, MYH7 pLOF and REVEL-informed pDM variant carriers were removed from
controls. Likewise, for echocardiographic comparison of carriers of pLOF and pDM with
REVEL≥0.5 variants in MYH7 versus controls, carriers of MYBPC3 pLOF and pathogenic
missense variants were removed from controls. All statistical analyses were completed using R
version 3.5 (Vienna, Austria).

31

3.3.7. Review of clinical charts
We reviewed the clinical charts of patients with HCM who also carry a pLOF or pDM
variant in MYBPC3 or MYH7 to assess the prevalence of clinical genetic testing for a molecular
diagnosis of carrying a pathogenic MYBPC3 or MYH7 variant. We also reviewed the clinical
charts of MYH7 pLOF carriers to characterize a cardiac phenotype among these individuals
without an HCM diagnosis. Finally, we interrogated the clinical charts of cases for “muscular
wasting and disuse atrophy” who also carried a pLOF or pDM variant in MYH7 to assess the
prevalence of clinical genetic testing for a molecular diagnosis of MYH7-related myopathy.

3.4. Results
3.4.1. pLOF variants in MYBPC3 were strongly associated with HCM
Among 41,759 unrelated individuals with WES in PMBB (Table 3.1), we identified 45
individuals carrying one of 33 predicted loss-of-function (pLOF) variants in MYBPC3, including 13
frameshift insertions/deletions, 9 gain of stop codon, and 11 splicing variants disrupting canonical
splice site dinucleotides (Figure 3.1.A; Appendix B, Table S1). PheWAS of the gene burden of
pLOF variants in MYBPC3 showed phenome-wide significant associations with HCM and related
cardiac phenotypes such as cardiac conduction disorders, heart failure, heart transplant/surgery,
and use of cardiac defibrillator (Table 3.2; Appendix B, Figure S1). 15 of the 45 individuals with a
rare pLOF had a clinical diagnosis of HCM (Phecodes “Hypertrophic obstructive cardiomyopathy”
or “Other hypertrophic cardiomyopathy”) (Appendix B, Table S1). 12 of 33 pLOFs were annotated
in ClinVar as pathogenic or likely pathogenic (P/LP), and of the 18 carriers of these P/LP variants,
6 had a clinical diagnosis of HCM. Of the 21 pLOF variants without a P/LP classification in
ClinVar, 9 were carried by a total of 9 individuals with diagnoses of HCM (Appendix B, Table S1).
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Basic demographics
Total population, N

41759

Female, N (%)

20731 (49.6)

Median age, years

63

Genetically informed ancestry
AFR, N (%)

10217 (24.5)

AMR, N (%)

572 (1.4)

EAS, N (%)

672 (1.6)

EUR, N (%)

29362 (70.3)

SAS, N (%)

564 (1.4)

Phecodes
Primary/intrinsic cardiomyopathies, N (%)

2912 (7.6)

Hypertrophic obstructive cardiomyopathy, N (%)

199 (0.6)

Other hypertrophic cardiomyopathy, N (%)

184 (0.5)

Cardiac dysrhythmias, N (%)

12130 (35.5)

Atrial fibrillation, N (%)

5885 (21.0)

Atrial flutter, N (%)

2324 (9.5)

Paroxysmal ventricular tachycardia, N (%)

1960 (8.2)

Ventricular fibrillation and flutter, N (%)

467 (2.1)

Cardiac conduction disorders, N (%)

5688 (20.5)

Cardiac pacemaker/device in situ, N (%)

3177 (12.6)

Cardiac defibrillator in situ, N (%)

1945 (8.1)

Congestive heart failure; nonhypertensive, N (%)

6224 (16.9)

Heart transplant/surgery, N (%)

792 (2.5)

Cardiac shunt/heart septal defect, N (%)

547 (1.4)

Cardiogenic shock, N (%)

188 (0.5)

Muscular wasting and disuse atrophy, N (%)

52 (0.1)

Table 3.1. Penn Medicine BioBank whole exome-sequenced cohort characteristics.
Basic demographic characteristics and representative Phecodes identified by gene burden PheWAS for
MYBPC3 and MYH7. Each characteristic is labeled with count data and percent prevalence where
appropriate. Individuals were determined to be a case for a Phecode if they had the corresponding ICD
diagnosis on two or more dates, while controls consisted of individuals who never had the ICD code.
Individuals with an ICD diagnosis on only one date as well as those under control exclusion criteria based on
Phecode mapping protocols were not considered. AFR-African, AMR-Mixed American, EAS-East Asian,
EUR-European, SAS-South Asian
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Figure 3.1. Distribution of disease-associated variants in MYH7 and MYBPC3. A) Schematic of
MYBPC3 gene with exons 1-35 (exons not to scale) above and domains below, with variants labeled in red
denoting amino acid change (or location of splice variant) for pLOF or adjudicated missense variants that
were associated with HCM in PMBB. B) Schematic of MYH7 gene with exons 1-41 (exons not to scale)
above and domains below. Variants are labeled in red denoting amino acid change for pDM variants with
REVEL≥0.5 that were associated with HCM in PMBB, and variants are labeled in blue denoting amino acid
change (or location of splice variant) for pLOF or pDM variants with REVEL≥0.5 that were associated with
“Muscular wasting and disuse atrophy” in PMBB. Note: exons 39-41, which do not encode for protein, are
grayed out. Note 2: p.M982T in MYH7 was associated with both HCM and muscular wasting and disuse
atrophy, but via different individuals, and is thus labeled in black.

Review of clinical charts of the 15 pLOF carriers with a clinical diagnosis of HCM
revealed that only 5 had a clinical genetic test report, all of which were concordant with the WES
pLOF results. While all 5 individuals with clinical genetic testing had a family history of HCM, only
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3 of 10 untested individuals had a family history of HCM noted in their charts. Chart review of the
30 MYBPC3 pLOF carriers without a clinical HCM diagnosis revealed that 17 had received at
least one transthoracic echocardiogram, and 8 of these individuals had left atrial enlargement
and/or hypertrophy of the septum or another segment within the left ventricle. Additionally, 10 of
30 pLOF carriers without a diagnosis of HCM had a history of atrial fibrillation.

MYBPC3
Gene Burden

Beta

SE

OR

P

Carrier N

HCM N

ClinVar P/LP (pLOF + missense)

4.177

0.453

65.161

3.15E-20

45

8

pLOF only

5.112

0.411

166.008

1.52E-35

45

15

pDM (REVEL≥0.6) only

0.908

0.316

2.48

4.05E-03

628

10

Adjudicated missense (SHaRe)

2.785

0.76

16.204

2.46E-04

22

2

pLOF + pDM

1.949

0.214

7.023

7.99E-20

673

25

pLOF + adjudicated missense

4.402

0.321

81.638

1.03E-42

67

17

MYH7
Gene Burden

Beta

SE

OR

P

Carrier N

HCM N

ClinVar P/LP (pLOF + missense)

4.737

0.301

11.404

1.29E-55

77

22

pLOF only

-10.658

315.401

2.35E-05

9.73E-01

27

0

pDM (REVEL≥0.5) only

2.059

0.183

7.839

2.01E-29

858

37

pLOF + pDM

2.033

0.183

7.635

9.23E-29

885
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Table 3.2. Association of MYBPC3 and MYH7 gene burdens with HCM in PMBB. Summary statistics for
gene burden associations with HCM (combining Phecodes “Hypertrophic obstructive cardiomyopathy” and
“Other hypertrophic cardiomyopathy”) in PMBB using ClinVar P/LP, pLOF only, missense only (pDM and/or
adjudicated), and pLOF + missense variants in MYBPC3 (top) and MYH7 (bottom). Each gene burden
association is reported as beta, standard error (SE), odds-ratio (OR), p value, the number of carriers for
variants included in the gene burden, and the number of carriers having the HCM phenotype.
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3.4.2. Predicted deleterious missense (pDM) variants in MYBPC3 were not associated with HCM
Based on ‘phenotype-first’ presentations of HCM, most pathogenic variants in MYBPC3
are pLOF variants.

55

ClinVar shows that 482 frameshift, nonsense, or splicing variants in

MYBPC3 are classified as P/LP, whereas only 54 missense variants are annotated as P/LP.

14

In

PMBB, the gene burden of all nonsynonymous coding variants in MYBPC3 classified by ClinVar
as P/LP (N=45 heterozygous carriers) was strongly associated with HCM as expected (Table 3.2;
Appendix B, Figure S2). However, while a gene burden of just the 12 pLOF variants classified as
P/LP (N=18 heterozygous carriers) also showed phenome-wide significant associations with
HCM Phecodes (Appendix B, Figure S3A), a gene burden of the 17 missense variants classified
as P/LP (N=27 heterozygous carriers) showed a much weaker association with HCM that was not
phenome-wide significant (p=9.50E-05) (Appendix B, Figure S3B). We previously have shown
that prediction of deleteriousness for missense variants using the ensemble tool REVEL
highly correlated with clinical annotations for missense variants in LMNA.

10

20

is

We similarly applied

REVEL to missense variants in MYBPC3 and found through an analysis of variance on ClinVarannotated variants that REVEL scores showed essentially no correlation with annotations of
clinical pathogenicity for MYBPC3 (Appendix B, Table S2). We experimented with REVEL score
thresholds in bins of 0.05 to evaluate the optimal score cutoff for capturing the most robust
association of missense variants in MYBPC3 associated with HCM. We found that all REVEL
cutoff thresholds showed very weak association with HCM, although a REVEL threshold score of
0.6 was relatively optimal (Table 3.2; Appendix B, Figure S4). Additionally, application of the
aggregation of predicted deleterious missense (pDM) variants chosen by a consensus of
algorithms (SIFT, PolyPhen2 HumDiv, PolyPhen2 HumVar, and MutationTaster)—one of the
standard approaches for predicting the deleteriousness of missense variants—also showed weak
association with HCM (Appendix B, Figure S4).
Given the weak or insignificant association of missense variants in MYBPC3 with HCM
based on algorithms predicting deleteriousness of missense variants alone, we overlapped a list
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of 19 expert-adjudicated pathogenic missense variants in MYBPC3 from the SHaRe Database to
identify high-confidence pathogenic missense variants in PMBB.
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We identified 6 of these high-

confidence pathogenic missense variants in MYBPC3 carried by a total of 22 individuals among
the PMBB WES cohort (Appendix B, Table S3). A gene burden including just these 6 missense
variants showed a similar degree of association with HCM compared to a gene burden of ClinVar
P/LP missense variants, and was more strongly associated with HCM compared to a burden of
pDM variants based on all REVEL score thresholds as well as 4/4 algorithms (Table 3.2;
Appendix B, Figure S4). 2 of the 22 carriers were diagnosed with HCM, and chart review of the
20 carriers without an HCM diagnosis revealed 5 individuals with mild concentric hypertrophy or
dilated atria noted on transthoracic echocardiography.
Including pDMs together with pLOFs in a gene burden has the potential to increase
power for finding phenotype associations. When we combined pLOFs with pDMs having
REVEL≥0.6, we noted no improvement in the association of the gene burden with HCM (Table
3.2). Only when the adjudicated pathogenic missense variants were included with pLOFs did we
see a stronger association with HCM compared with pLOFs alone (Figure 3.2, Table 3.2). We
further interrogated this MYBPC3 gene burden combining pLOFs and adjudicated pathogenic
missense variants by analyzing available echocardiography data in PMBB. Carriers of pLOF and
adjudicated pathogenic missense variants in MYBPC3 on average had increased left ventricular
posterior wall (LVPW) diastolic thickness, interventricular septum (IVS) diastolic thickness, left
atrial (LA) volume index, and left ventricular outflow tract (LVOT) peak gradient (Table 3.3)
compared to non-carriers, although not always at clinically relevant thresholds.
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Figure 3.2. Gene burden PheWAS of pLOF and adjudicated pathogenic missense variants in
MYBPC3. Gene burden PheWAS of pLOF variants (N=45, Appendix B, Table S1) and adjudicated
pathogenic missense variants from SHaRE (N=22, Appendix B, Table S3) in MYBPC3. Phecodes are
plotted along the x axis to represent the phenome, and the association of the gene burden with each
Phecode is plotted along the y axis representing –log10(p value). The red line represents the Bonferronicorrected significance threshold to adjust for multiple testing (p=3.58E-05), and the blue line represents a
nominal significance threshold (p=0.05).

3.4.3. pLOF variants in MYH7 were not significantly associated with HCM but had suggestive
associations with other cardiac phenotypes
We identified 27 individuals carrying one of 23 pLOF variants in MYH7, including 5
frameshift insertion/deletions, 13 gain of stop codon, and 5 splicing variants (Appendix B, Table
S4). Of note, none of these pLOF variants were in the last exon of MYH7. In contrast to MYBPC3,
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PheWAS of the MYH7 pLOF only gene burden showed no association with HCM (p=0.973)
(Table 3.2; Appendix B, Figure S5). We confirmed through chart review that none of the 27 pLOF
carriers had an HCM diagnosis (Appendix B, Table S4). Interestingly, however, this pLOF gene
burden had weak evidence for association with “Cardiac shunt/heart septal defect” (p=1.12E-04,
N=3), suggesting the possibility of a cardiac phenotype among heterozygous carriers for pLOF
variants in MYH7. Detailed review of the clinical charts of the 27 MYH7 pLOF carriers confirmed a
history of patent foramen ovale or atrial septal defect in 3 pLOF carriers, and also revealed that
13 of 27 had received echocardiograms, of which 5 individuals had mild concentric left ventricular
hypertrophy.

Echo Parameter

MYBPC3 Median
(IQR)

Control Median
(IQR)

Beta

SE

P

MYBPC3
N

Control
N

LVPW diastolic
thickness, max
(cm)

1.320
(1.160, 1.525)

1.100
(0.951, 1.284)

0.257

0.043

2.86E-09

31

11928
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thickness, max
(cm)

1.510
(1.203, 1.871)

1.150
(0.989, 1.340)

0.414

0.050

7.68E-17

30

11854

LA volume index,
max (mL/m^2)

48.593
(40.224, 52.374)

33.725
(24.929, 44.948)

12.567

3.744

7.89E-04

22

8128

LVOT peak
gradient, max
(mmHg)

6.554
(4.162, 9.000)

4.410
(3.254, 6.052)

2.605

0.500

1.91E-07

29
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Echo Parameter

MYH7 Median
(IQR)

Control Median
(IQR)

Beta

SE

P

MYH7
N

Control
N

LVPW diastolic
thickness, max
(cm)

1.130
(0.934, 1.285)

1.100
(0.951, 1.284)

0.045

0.014

1.63E-03

303

11928

IVS diastolic
thickness, max
(cm)

1.190
(1.001, 1.390)

1.150
(0.989, 1.340)

0.071

0.016

1.09E-05

300

11854

LA volume index,
max (mL/m^2)

36.796
(27.763, 50.182)

33.725
(24.929, 44.948)

5.235

1.242

2.51E-05

214

8128

LVOT peak
gradient, max
(mmHg)

4.801
(3.467, 6.554)

4.410
(3.254, 6.052)

0.458

0.187

1.41E-02

222

8807

Table 3.3. Echocardiographic analyses for MYBPC3 and MYH7 in PMBB. Top: comparison of
echocardiographic parameters representative of HCM with gene burden of pLOF variants and adjudicated
pathogenic missense variants from SHaRE in MYBPC3 versus non-carriers. Carriers of pLOF variants and

39

pDM variants with REVEL≥0.5 in MYH7 were removed from this analysis. Median and interquartile ranges
(IQR) for each echo parameter are listed for each test group, and association results are listed as beta,
standard error (SE), and p value. The number of individuals with each echo parameter available are also
listed per test group. Bottom: comparison of echocardiographic parameters representative of HCM with gene
burden of pLOF variants and pDM variants with REVEL≥0.5 in MYH7 versus non-carriers. Carriers of pLOF
variants and adjudicated pathogenic missense variants from SHaRE in MYBPC3 were removed from this
analysis. Median and interquartile ranges (IQR) for each echo parameter are listed for each test group, and
association results are listed as beta, standard error (SE), and p value. The number of individuals with each
echo parameter available are also listed per test group. LVPW – left ventricule posterior wall, IVS –
interventricular septum, LA – left atrial, LVOT – left ventricular outflow tract

3.4.4. Predicted deleterious missense (pDM) variants in MYH7 were strongly associated with
HCM
56

Most known pathogenic variants in MYH7 are missense , as exemplified by the ClinVar
database which has classified 272 missense variants in MYH7 as P/LP, whereas there are only
20 frameshift, nonsense, or splicing variants annotated as P/LP.

14

In PMBB, we found a total of

43 missense variants annotated by ClinVar as P/LP (N=75 heterozygous carriers) as well as just
two pLOFs annotated as P/LP (N=2 carriers). As expected, a gene burden comprised only of
these ClinVar P/LP nonsynonymous variants had a very strong association with HCM (Table 3.2;
Appendix B, Figure S6). Of the 75 carriers with ClinVar P/LP missense variants, 22 had a
diagnosis of HCM, while neither of the two carriers for pLOFs annotated in ClinVar as P/LP had
an HCM diagnosis.
We then asked how a computational approach to selecting MYH7 missense variants
would perform and explored in detail the association of pDM variants in MYH7 with HCM and
other phenotypes. We applied REVEL to missense variants in MYH7 and found through an
analysis of variance on ClinVar-annotated variants that REVEL scores were highly correlated with
annotations of clinical pathogenicity for MYH7 (Appendix B, Table S5). We then experimented
with REVEL score thresholds in bins of 0.05 to evaluate the optimal score cutoff for capturing the
most robust association of missense variants in MYH7 with HCM, with the goal of potentially
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capturing deleterious missense variants in MYH7 that lack a pathogenic ClinVar classification.
We found that a REVEL cutoff score of 0.5 had the optimal p value for association of MYH7 pDM
variants with HCM (Table 3.2; Appendix B, Figure S7). Of note, this REVEL-based association
was more strongly associated with HCM compared to the aggregation of pDM variants predicted
deleterious by a consensus of algorithms (SIFT, PolyPhen2 HumDiv, PolyPhen2 HumVar, and
MutationTaster), even while identifying more variants (303 variants with REVEL≥0.5 vs. 166
variants passing consensus of algorithms) (Appendix B, Figure S7). The HCM-prevalent
missense variants were concentrated among the globular S1 head and coiled-coil S2 domains of
MYH7 (Figure 3.1.B; Appendix B, Table S6). Among 858 total carriers for pDM variants in MYH7
with REVEL≥0.5, 37 heterozygous carriers for 33 different pDM variants had a diagnosis of HCM
(Appendix B, Table S6). 15 MYH7 pDM variants with REVEL≥0.5 lacking a classification of P/LP
in ClinVar were carried by individuals with a diagnosis of HCM (Appendix B, Table S6). Chart
review of these 37 carriers confirmed the diagnosis of HCM and indicated that only 15 of the 37
carriers had clinical genetic testing for HCM in their chart (all were concordant with the WES
MYH7 variant). While 13 of 15 individuals with a clinical genetic test in the chart noted a family
history of HCM, only half of untested individuals had a documented family history.

3.4.5. Gene burden of pLOF and pDM variants in MYH7 was also associated with a skeletal
muscle phenotype
In order to increase power for finding associations, we aggregated the 23 pLOF variants
in MYH7 (N=27 carriers) with the 303 pDM variants with REVEL≥0.5 in MYH7 (N=858 carriers)
into a gene burden. PheWAS of this combined MYH7 gene burden showed, as expected,
phenome-wide significant associations with HCM (Figure 3.3, Table 3.2), but the strength of this
association was not greater than with a pDM gene burden alone. This expanded gene burden
was also significantly associated with related cardiac phenotypes “Heart transplant/surgery” and
“Cardiac defibrillator in situ” (Figure 3.3). We also linked the expanded gene burden with available
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echocardiography data in PMBB, and found that carriers of pLOF and pDM variants in MYH7 on
average had increased left ventricular posterior wall (LVPW) diastolic thickness, interventricular
septum (IVS) diastolic thickness, left atrial (LA) volume index, and left ventricular outflow tract
(LVOT) peak gradient (Table 3.3) compared to non-carriers, although not always at clinically
relevant thresholds.

Figure 3.3. Gene burden PheWAS of pLOF + pDM variants in MYH7. Gene burden PheWAS of pLOF
variants (N=27, Appendix B, Table S4) and pDM variants with REVEL≥0.5 (N=858, Appendix B, Table S6) in
MYH7. Phecodes are plotted along the x axis to represent the phenome, and the association of the gene
burden with each Phecode is plotted along the y axis representing –log10(p value). The red line represents
the Bonferroni-corrected significance threshold to adjust for multiple testing (p=3.58E-05), and the blue line
represents a nominal significance threshold (p=0.05).
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Additionally, we found a phenome-wide significant association with “Muscular wasting
and disuse atrophy” with this expanded gene burden (Figure 3.3) that was not seen with the gene
burden limited to ClinVar P/LP variants alone (Appendix B, Figure S6). We identified 1 pLOF
variant and 4 missense variants with REVEL≥0.5 carried by a total of 7 individuals who had the
Phecode of “Muscular wasting and disuse atrophy” (Figure 3.1.B; Appendix B, Table S4, Table
S6). Of note, all 5 variants lacked a P/LP classification in ClinVar, and none of the 7 individuals
had a diagnosis for HCM. Chart review of these individuals revealed secondary myopathy and
generalized muscular wasting rather than a primary myopathy diagnosis. Of those individuals with
electromyography performed, none revealed a primary neuromuscular diagnosis. We also
compared available serum creatine kinase (CK) measurements between carriers for pLOF
variants or pDM with REVEL≥0.5 in MYH7 (total of 73 carriers with CK available) versus all noncarriers, and there was no significant association between the MYH7 gene burden and CK
concentrations (p=0.549).

3.5. Discussion
Gene burden PheWAS applied to large healthcare-based biobanks has the potential to
elucidate the medical consequences of gene variants on the human disease phenome.

22

A logical

first step is to perform PheWAS focused only on predicted loss-of-function (pLOF) variants, which
has the advantage of interrogating the largest effect sizes that a gene burden may have on
associated phenotypes, but could lead to lack of power due to their infrequency. In aggregating
pLOF variants in MYBPC3 and MYH7 for gene burden PheWAS in PMBB, only the MYBPC3
pLOF gene burden was associated with HCM, while the MYH7 pLOF gene burden was
associated with other cardiac phenotypes and not HCM. This is an expected finding given that
truncating variants account for >90% of cases of MYBPC3 HCM,
variants have a demonstrated association with HCM.
43

58

57

while only missense MYH7

Furthermore, detailed review of clinical

charts confirmed a diagnosis of HCM among a subset of MYBPC3 pLOF carriers while revealing
mild concentric left ventricular hypertrophy and patent foramen ovale or atrial septal defect
among a subset of MYH7 pLOF carriers. Functional studies have shown that pLOF variants in
MYBPC3 promote nonsense-mediated decay pathways to contribute to the pathogenesis of HCM
through haploinsufficiency.
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pLOF variants in MYH7, on the other hand, are not associated

with HCM; however, recently pLOF variants in MYH7 have been associated with left ventricular
noncompaction cardiomyopathy, which has low diagnostic accuracy on echocardiography and
thus could have been missed in our review of clinical charts.
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In principle, missense variants could be combined with pLOFs to substantially increase
the number of effect alleles and power for novel discovery, but a major challenge is deciding
which variants to include in gene burden tests of association. Including predicted deleterious
missense (pDM) variants based on in silico prediction algorithms in addition to pLOFs in gene
burdens increases power for disease associations in some genes, but the performance of such
algorithms for missense variants may not be consistent across all genes. Our interrogation of
missense variants based on prediction algorithms like REVEL serves as a testament to this
notion; while pDM variants in MYH7 showed strong correlation with clinical annotations of
pathogenicity as well as strong associations with the expected HCM phenotype in PMBB,
predictions of deleteriousness for missense variants in MYBPC3 did not correlate with clinical
annotations of pathogenicity and were not associated with HCM. The difference in performance
may be due to different mechisms of HCM pathogenesis. For example, MYH7 missense variants
exert dominant negative effects on sarcomeric function, while haploinsufficiency and allelic
imbalance in MYBPC3 is the major mechanism leading to HCM.

61,62

Importantly, these differences show that aggregating only pLOFs for gene burden
association testing may be more appropriate for some genes like MYBPC3, while inclusion of
additional pDM variants chosen based on in silico predictions may be more beneficial for
increasing the number of effect alleles for others like MYH7, as we have similarly shown for
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LMNA.

10

Additionally for MYBPC3, in which in silico prediction of missense variants performed

poorly, we show that expert-adjudication of annotations of pathogenicity for missense variants
based on in vitro and in silico analyses of missense variants in SHaRe, the largest
comprehensive HCM cohort assembled to date, is superior in selecting missense variants for
addition to gene burden testing.
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For other genes in which in silico predictions perform poorly

for missense variants, we suggest that high-confidence pathogenic missense variants be added
after expert adjudication to a degree that essentially parallels a saturated mutagenesis
experiment.
A key goal in precision medicine initiatives is to promote a platform by which healthcare
providers can make accurate diagnoses based on a wide variety of personalized health data,
including individuals’ genetic information. Genetic testing of patients with HCM can identify the
precise genetic cause of disease, improve diagnostic accuracy in a patient with an ambivalent
diagnosis, and allow for cascade screening in family members.
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However, pathogenic HCM-

causing variants found on more comprehensive sequencing can also be missed in clinical
practice, which makes the genome-first approach applied to WES for review of clinical charts for
carriers of pathogenic and potentially deleterious variants crucial.
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Our review of clinical charts

revealed that a substantial number of patients clinically diagnosed with HCM did not appear to
have had genetic testing, including those who were found in WES to have a pathogenic HCMassociated variant in MYBPC3 or MYH7. We found that about a third of these HCM individuals
without a genetic diagnosis were diagnosed with HCM before age 30. We also noted that patients
with HCM without a genetic test in their chart had a significantly lower rate of a family history of
HCM versus those who received genetic testing. While genetic testing is now routinely offered in
specialized cardiomyopathy clinics, it is still broadly underutilized and patients may benefit from
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referral to specialized HCM clinics for genetic diagnosis and family screening.

Additionally, we

found that on average carriers for P/LP or predicted deleterious variants without a diagnosis of
HCM had increased LA size and LV wall thickness compared to non-carriers, subclinical features
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that may warrant clinical follow-up when noted on echocardiography. Importantly, many carriers
for P/LP or predicted deleterious variants without a diagnosis of HCM had no clinical or
echocardiographic evidence of cardiac disease, showing the value of a genome-first approach for
estimating penetrance of single-gene Mendelian disorders like HCM.
A major advantage of the genome-first approach to conducting gene burden PheWAS is
the potential to capture pleiotropy. We found that the pLOF + pDM (REVEL ≥ 0.5) gene burden
for MYH7 had phenome-wide significant associations with both HCM and “Muscular wasting and
disuse atrophy.” Importantly, while MYBPC3 is specifically expressed in the heart, MYH7 is also
expressed in skeletal muscle,
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and MYH7-related myopathies are an emerging and

underdiagnosed group of muscle diseases of childhood and adulthood.
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It has been reported

that variants in MYH7 which cause skeletal muscle disorders may cluster in the distal regions of
the rod domain (light meromyosin domain, LMM with or without cardiac involvement).
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We found

that myopathy-associated variants in MYH7 were located in the neck and hinge (distal S1 and S2
domains) of MYH7 from exons 18-24, suggesting that variants which affect skeletal muscle
function may not be limited to the LMM domain. Of note, patients diagnosed with “muscular
wasting and disuse atrophy” who carried a predicted deleterious MYH7 variant did not have a
primary myopathy diagnosis but rather had secondary muscular wasting, indicating that MYH7related myopathy may be a ‘second hit’ phenomenon that can be unmasked by comorbidities.
In conclusion, we used a genome-first approach to include pLOFs and selected missense
variants in MYBPC3 and MYH7 in gene burdens to show their significant associations with HCM,
as well as the MYH7-specific association with myopathy. We demonstrate gene-specific
differences in appropriate coding variant selection for gene burden testing to uncover important
clinical and subclinical features relevant to associated diseases implicated by predicted
deleterious variants. Our approach also suggests an expanded opportunity for clinical genetic
evaluation and referral to multidisciplinary HCM centers. Importantly, our study demonstrates the
value of assessing both pLOF and pDM variants for gene burden testing in future studies to
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uncover novel gene-disease relationships and identify novel pathogenic loss-of-function variants
across the human genome through genome-first analyses of healthcare-based populations.
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CHAPTER 4. Exome-wide evaluation of rare coding variants
using electronic health records identifies new gene-phenotype
associations

This thesis chapter was adapted from:
Park J, Lucas AM, Zhang X, Chaudhary K, Cho JH, Nadkarni G, Dobbyn A, Chittoor G, Josyula
NS, Katz N, Breeyear JH, Ahmadmehrabi S, Drivas TG, Chavali VRM, Fasolino M, Sawada H,
Daugherty A, Li Y, Zhang C, Bradford Y, Weaver J, Verma A, Judy RL, Kember RL, Overton JD,
Reid JG, Ferreira MAR, Li AH, Baras A, LeMaire SA, Shen YH, Naji A, Kaestner KH, Vahedi G,
Edwards TL, Chen J, Damrauer SM, Justice AE, Do R, Ritchie MD, Rader DJ. Exome-wide
evaluation of rare coding variants using electronic health records identifies new gene-phenotype
associations. Nature Medicine. 2021 Jan;27(1):66-72. doi: 10.1038/s41591-020-1133-8.

4.1. Abstract
The clinical impact of rare loss-of-function variants has yet to be determined for most genes.
Integration of DNA sequencing data with electronic health records (EHR) could enhance our
8

understanding of the contribution of rare genetic variation to human disease. By leveraging
10,900 whole exome sequences linked to EHR data in the Penn Medicine BioBank (PMBB), we
addressed the association of the cumulative effects of rare predicted loss-of-function (pLOF)
variants per individual gene on human disease on an exome-wide scale, as assessed using a set
of diverse EHR phenotypes. After discovering 97 genes with exome-by-phenome-wide significant
-6

phenotype associations (p < 10 ), we replicated 26 of these in PMBB, as well as in three other
medical biobanks and the population-based UK Biobank (UKB). Of these 26 genes, five had
associations that have been previously reported and represented positive controls, whereas 21
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had phenotype associations not previously reported, among which were genes implicated in
glaucoma, aortic ectasia, diabetes mellitus, muscular dystrophy, and hearing loss. These findings
show the value of aggregating rare pLOF variants into “gene burdens” for identifying new genedisease associations using EHR phenotypes in a medical biobank. We suggest that application of
this approach to even larger numbers of individuals will provide the statistical power required to
uncover unexplored relationships between rare genetic variation and disease phenotypes.

4.2. Introduction
A “genome-first” approach, in which genetic variants of interest are identified and then
subsequently associated with phenotypes, has the potential to inform the genetic basis of human
6

disease and reveal new insights into gene function and human biology. This approach can be
applied to “medical” biobanks consisting of healthcare populations with DNA sequence data
linked to extensive EHR phenotype data, thus permitting “phenome-wide association studies”
(PheWAS) as an agnostic approach to determining the clinical impact of specific genetic
9

variants. Genome-first approaches utilizing PheWAS have primarily focused on individual
common variants of modest effect.

12

Very rare and private coding variants are more likely to have

larger effect sizes and are of great interest, but are generally too rare to study in a univariate
fashion.

11

Aggregation of multiple rare variants in a gene (i.e. “gene burden”) not only increases

the statistical power of regression analyses but also enables gene-based association studies to
describe the clinical implications of loss of gene function in human disease.

13

Previously, we leveraged the Penn Medicine BioBank (PMBB, University of
Pennsylvania), a large academic medical biobank with whole-exome sequencing (WES) data
linked to EHR data, to show that aggregating rare, loss-of-function variants in a single gene or
targeted sets of genes to conduct gene burden PheWAS has the potential to uncover novel
pleiotropic relationships between the gene and human disease.
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We applied rare pLOF-based

gene burden PheWAS on an exome-wide scale, utilizing WES data to conduct exome-byphenome-wide association studies (ExoPheWAS) to evaluate in detail the clinical phenotypes
(i.e. phecodes) associated with rare pLOF variants on a gene-by-gene basis across the human
exome, and replicated our top results in several other medical biobanks.

4.3. Materials and Methods
4.3.1. Setting and study participants
All individuals who were recruited for the Penn Medicine BioBank (PMBB) are patients of
clinical practice sites of the University of Pennsylvania Health System. Appropriate consent was
obtained from each participant regarding storage of biological specimens, genetic sequencing,
access to all available electronic health record (EHR) data, and permission to recontact for future
studies. The study was approved by the Institutional Review Board of the University of
Pennsylvania and complied with the principles set out in the Declaration of Helsinki.
In addition to our robustness validation analyses within PMBB, replication analyses were
conducted using the WES dataset from an additional set of independent African-American
individuals in PMBB (PMBB2), BioMe, DiscovEHR, UK Biobank (UKB), as well as imputed
genotype data in BioVU, for evaluation of the robustness of gene-phenotype associations
identified in PMBB. For replication analyses in BioMe, DiscovEHR, and BioVU, each study was
approved by the Institutional Review Board of each respective biobank’s institution. Access to the
UK Biobank for this project was from Application 32133.

4.3.2. Genetic sequencing
This PMBB study dataset included a subset of 11,451 individuals in the PMBB who have
undergone whole-exome sequencing (WES). For each individual, we extracted DNA from stored
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buffy coats and then obtained exome sequences generated by the Regeneron Genetics Center
(Tarrytown, NY). These sequences were mapped to GRCh37 as previously described.

10

Furthermore, for subsequent phenotypic analyses, we removed samples with low exome
sequencing coverage (i.e. less than 75% of targeted bases achieving 20x coverage), high
missingness (i.e. greater than 5% of targeted bases), high heterozygosity, dissimilar reported and
genetically determined sex, genetic evidence of sample duplication, and cryptic relatedness (i.e.
rd

closer than 3 degree relatives), leading to a total of 10,900 individuals.
For replication studies in PMBB2, we interrogated an additional 6,935 individuals of
African American ancestry in PMBB who were exome-sequenced by the Regeneron Genetics
Center. We focused our replication efforts on 6,432 individuals after removing samples with poor
rd

genotype quality, individuals closer than 3 degree relatives, and those with dissimilar reported
and genetically determined sex. These sequences were mapped to GRCh38.
For replication studies in BioMe, we interrogated 6,470 individuals of African ancestry,
8,735 individuals of European ancestry, and 8,784 individuals of Hispanic ancestry with WES
data linked to EHR diagnosis phenotypes after removing samples with poor genotype quality,
rd

individuals closer than 3 degree relatives, and those with dissimilar reported and genetically
determined sex. These sequences were mapped to GRCh38.
For replication studies in DiscovEHR, we interrogated 70,734 individuals of European
ancestry exome-sequenced on the IDT platform and a separate set of 59,133 individuals of
European ancestry exome-sequenced on the VCRome platform. We focused our replication
efforts on 85,450 individuals (N=48,413 for IDT, N=37,037 for VCRome) after removing samples
rd

with poor genotype quality, individuals closer than 3 degree relatives, those with dissimilar
reported and genetically determined sex, and those that self-identified as Hispanic/Latino. These
sequences were mapped to GRCh38.
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For replication studies in UKB, we interrogated the 34,629 individuals of European
ancestry (based on UKB’s reported genetic ancestry grouping) with ICD-10 diagnosis codes
available among the 49,960 individuals who had WES data as generated by the Functional
Equivalence (FE) pipeline. We focused our replication efforts on 32,268 individuals after removing
rd

samples with poor genotype quality, individuals closer than 3 degree relatives, and those with
dissimilar reported and genetically determined sex. The PLINK files for exome sequencing
provided by UKB were based on mappings to GRCh38.
For replication studies in BioVU, which has genotype but not large-scale WES data, we
focused on a select group of single variants that showed replication in PMBB, PMBB2, and/or
UKB. We interrogated these variants for association with specific phecodes in 10,456 individuals
of African American ancestry and 55,944 individuals of European ancestry after removing
samples with poor genotype quality, individuals closer than 3rd degree relatives, and those with
dissimilar reported and genetically determined sex. These sequences were mapped to GRCh37.
Additional information regarding population characteristics, recruitment, and ethical
oversight can be found in the Life Sciences Reporting Summary of this study.

4.3.3. Variant annotation and selection for association testing
For all cohorts analyzed, genetic variants were annotated using ANNOVAR (version
2018Apr16)
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as predicted loss-of-function (pLOF) or missense variants according to the NCBI

Reference Sequence (RefSeq) database. pLOF variants were defined as frameshift
insertions/deletions, gain/loss of stop codon, or disruption of canonical splice site dinucleotides.
Predicted deleterious missense (pDM) variants were defined as those with Rare Exonic Variant
Ensemble Learner (REVEL)

20

scores ≥ 0.5. Minor allele frequencies for each variant were

determined per Non-Finnish European, African, and Latino minor allele frequencies reported by
the Genome Aggregation Database (gnomAD) v2.
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pLOF and REVEL-informed missense

variants were selected for gene burden testing or univariate association analyses per ancestry
group in each cohort according to each ancestry’s corresponding ancestry-specific minor allele
frequency thresholds (rare variants with MAF ≤ 0.1% for gene burden testing, single variants with
MAF > 0.1%).

4.3.4. Clinical data collection
International Classification of Diseases Ninth Revision (ICD-9) and Tenth Revision (ICD10) disease diagnosis codes and procedural billing codes, medications, and clinical imaging and
laboratory measurements were extracted from the patients’ EHR for PMBB. ICD-10 encounter
diagnoses were mapped to ICD-9 via the Center for Medicare and Medicaid Services 2017
General Equivalency Mappings (https://www.cms.gov/Medicare/Coding/ICD10/2017-ICD-10-CMand-GEMs.html) and manual curation. Phenotypes for each individual were then determined by
mapping ICD-9 codes to distinct disease entities (i.e. phecodes) via Phecode Map 1.2 using the
R package “PheWAS”.
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Patients were determined to have a certain disease phenotype if they

had the corresponding ICD diagnosis on two or more dates, while phenotypic controls consisted
of individuals who never had the ICD code. Individuals with an ICD diagnosis on only one date as
well as individuals under control exclusion criteria based on PheWAS phenotype mapping
protocols were not considered in statistical analyses.
All laboratory values measured in the outpatient setting were extracted for participants
from the time of enrollment in PMBB until March 20, 2019; all units were converted to their
respective clinical Traditional Units. Minimum, median, and maximum measurements of each
laboratory measurement were recorded for each individual and used for all association analyses.
Inpatient and outpatient echocardiography measurements were extracted if available for
participants from January 1, 2010 until September 9, 2016; outliers for each echocardiographic
parameter (less than Q1 - 1.5*IQR or greater than Q3 + 1.5*IQR) were removed. Similarly,
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minimum, median, and maximum values for each parameter were recorded for each patient and
used for association analyses.
ICD-9 and ICD-10 codes were similarly mapped to phecodes in PMBB2, BioMe,
DiscovEHR, and BioVU for replication studies. For UKB, we used the provided ICD-10 disease
diagnosis codes for replication studies, and individuals were determined to have a certain disease
phenotype if they had one or more encounters for the corresponding ICD diagnosis given the lack
of individuals with more than two encounters per diagnosis, while phenotypic controls consisted
of individuals who never had the ICD code. Individuals under control exclusion criteria based on
PheWAS phenotype mapping protocols were not considered in statistical analyses.

4.3.5. Association studies
A phenome-wide association study (PheWAS) approach was used to determine the
phenotypes associated with rare (MAF ≤ 0.1% in gnomAD) pLOF variants carried by individuals
in PMBB for the discovery experiment.
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Each disease phenotype was tested for association with
2

each gene burden or single variant using a logistic regression model adjusted for age, age , sex,
and the first ten principal components (PCs) of genetic ancestry. We used an additive genetic
35

model to collapse variants per gene via the fixed threshold approach.

Given the high

percentage of individuals of African ancestry present in the discovery PMBB cohort, association
analyses were performed separately in European (N=8,198) and African (N=2,172) genetic
ancestries and combined with inverse variance weighted meta-analysis. Only genes with at least
25 carriers of pLOFs were analyzed in the discovery analysis (N=1,518). Our association
analyses considered only disease phenotypes with at least 20 cases, leading to the interrogation
of 1,000 total phecodes. All association analyses were completed using R version 3.3.1 (Vienna,
Austria). Power analyses were conducted using QUANTO version 1.2.4.
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We further evaluated the robustness of our gene-phenotype associations in the same
PMBB discovery cohort by 1) associating the aggregation of rare (MAF ≤ 0.1%) pDM variants in
gene burden association tests and 2) testing pLOFs and pDM variants with MAF > 0.1 in
univariate association tests. We ensured that individuals were non-overlapping across rare
pLOFs, rare deleterious missense, and single variant groups. Rare deleterious missense gene
burdens and single variants were analyzed for association with the specific phenotype identified
in the pLOF-based gene burden discovery, as well as with related phenotypes in their
corresponding phecode families (integer part of phecode). For example, to replicate an
association of a gene burden with hypothetical phecode 123.45, we associated other variants in
the same gene with phecode 123.45 as well as other related phenotypes under the phecode
family 123 (e.g. 123.6). Notably, we checked for the presence of mutual carriers between each
gene’s pLOF-based gene burdens and subsequently interrogated missense-based gene burdens
or single variants due to linkage disequilibrium and/or rare chance, and only reported replications
for which the significant phenotypes’ associations were not being driven by mutual carriers. All
2

association studies in PMBB were based on a logistic regression model adjusted for age, age ,
sex, and the first 10 PCs of genetic ancestry.
Additionally, we replicated our findings in PMBB2, BioMe, DiscovEHR, and UKB for
genes of interest using pLOF-based gene burden, REVEL-informed missense-based gene
burden, and/or univariate association analyses from discovery in PMBB. A specific set of single
variants were further replicated in BioVU. Association statistics were calculated similarly to
PMBB, such that each disease phenotype was tested for association with each gene burden or
2

single variant using a logistic regression model adjusted for age, age , sex, and the first 10 PCs
of genetic ancestry. In BioMe, the summary statistics obtained from running the logistic
regression model separately in individuals of European, African, and Hispanic ancestry were
meta-analyzed. In DiscovEHR, the summary statistics obtained from running the logistic
regression model separately in individuals of European ancestry on the IDT versus VCRome
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platforms were meta-analyzed. In BioVU, the summary statistics obtained from running the
logistic regression model separately in individuals of European and African ancestry were metaanalyzed. All association analyses for PMBB, PMBB2, BioMe, DiscovEHR, UK Biobank, and
BioVU were completed using R version 3.3.1 or later (Vienna, Austria). Further information about
association studies in each cohort can be found in the Life Sciences Reporting Summary of this
study.

4.3.6. Undercalling of variants in UK Biobank
Given the undercalling of variants largely limited to ~3.25% of the exome target regions in
the FE pipeline data, we found that 3 of the 97 genes having associations with p<E-06 from the
discovery phase overlap with the undercalled exonic regions, namely CES5A, CYP2D6, and
ZC3H3. While all other analyses in this study included variants with less than 5% missingness,
we included variants with at least 65% call rate for these three genes, understanding that
undercalling per variant is random per individual.

4.3.7. Statistical analyses of clinical measurements
In order to compare available measurements for echocardiographic parameters and
serum laboratory values between carriers of predicted deleterious variants and genotypic controls
2

in PMBB, we utilized linear regression adjusted for age, age , sex, and the first 10 PCs of genetic
ancestry in individuals of European ancestry only. These analyses were conducted with the
minimum, median, and maximum value as the dependent variable for each echocardiographic
parameter and clinical lab measure. All statistical analyses, including PheWAS, were completed
using R version 3.3.1 or later (Vienna, Austria).
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4.3.8. Chart review to validate robust gene-phenotype associations
To confirm our curated list of robust exome-by-phenome-wide significant associations,
we manually chart reviewed the EHR for each carrier of rare pLOF variants in genes that showed
at least one mode of replication in any cohort. Importantly, for each gene, we aimed to adjudicate
the diagnoses of carriers who were flagged as cases for the relevant associated phenotype. We
removed associations for which chart review reduced the prevalence of the diagnosis among
carriers and thus changed the association to p > E-06. Furthermore, we removed associations for
which chart review could not identify a common underlying etiology among all cases for the
diagnosis, paying special attention to phecodes that group “other” diagnoses that do not fit into
disease-specific ICD codes (i.e. “other diseases of blood and blood-forming organs”).
We discovered on chart review that individuals who were cases for phecodes
“hypertrophic obstructive cardiomyopathy” or “other hypertrophic cardiomyopathy” in PMBB were
patients with hypertrophic cardiomyopathy who were being assigned one of the codes due to the
lack of a single ICD diagnosis code for hypertrophic cardiomyopathy. Thus, we defined a new
phenotype for hypertrophic cardiomyopathy encompassing cases for either phecode, and
repeated the association with the pLOF gene burdens of MYBPC3 (positive control) and BBS10
(novel), and confirmed their associations as exome-by-phenome-wide significant (Appendix C,
Table S22).

4.3.9. Analysis of publicly available expression datasets from NCBI GEO
We interrogated microarray and RNA-seq data publicly available on the NCBI Gene
Expression Omnibus (GEO) platform (https://www.ncbi.nlm.nih.gov/geo/).
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To investigate the

novel association between CILP and aortic ectasia, we interrogated 11 different microarray and
RNA-seq datasets of human fibroblasts from various tissues treated with TGF-ß (GSE1724,
GSE65069, GSE64192, GSE39394, GSE79621, GSE68164, GSE97833, GSE97823,
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GSE135065, GSE125519, GSE40266). Differential expression for each dataset was interrogated
using the GEO2R software via a moderated t-statistic. Meta-analysis of differential expression
across the datasets was achieved using the Fisher’s combined probability test. Visualization of
the meta-analyzed differential expression was achieved using the R package “MetaVolcanoR
1.0.1”. Identification of the top 1% of differentially expressed genes across all datasets was
achieved using the Topconfects method.
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We also analyzed microarray data from muscle biopsies in tibial muscular dystrophy
patients versus control (GSE42806) to validate the novel association between MYCBP2 and
muscle spasms. Differential expression was interrogated using the GEO2R software via a
moderated t-statistic.

4.3.10. In silico analyses for PPP1R13L expression in ocular tissues
To understand the functional relevance of PPP1R13L in the eye, we evaluated its
expression in human ocular tissues using the publicly available Ocular Tissue Database (OTDB;
https://genome.uiowa.edu/otdb/).
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The OTDB consists of gene expression data for eye tissues

from 20 normal human donors, generated using Affymetrix Human Exon 1.0 ST arrays and
described as Probe Logarithmic Intensity Error (PLIER) values, where individual gene expression
values are normalized with its expression in other tissues.

4.3.11. Gene expression in DBA/2J mouse ocular tissues
We assessed the gene expression of Ppp1r13l in mouse ocular tissues using the publicly
available Glaucoma Discovery Platform (http://glaucomadb.jax.org/glaucoma). This platform
provides an interactive way to analyze RNA sequencing data obtained from retinal ganglion cells
(RGCs) isolated from retina and optic nerve head of a 9-month-old female D2 mouse, which is an
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+

age-dependent model of ocular hypertension/glaucoma, and D2-Gpnmb mouse that do not
develop high IOP/glaucoma.
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For transcriptomic studies, four distinct groups were compared

based on axonal degeneration and gene expression patterns. The transcriptome of D2 group 1 is
+

identical to the control strain (D2-Gpnmb ), while D2 groups 2–4 exhibit increasing levels of
molecular changes relevant to axonal degeneration when compared to control group. We used
the Datgan software to assess the differential expression of Ppp1r13l in the retina.
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4.3.12. Immunolocalization of PPP1R13L in human retina
To study the localization of PPP1R13L protein in different retinal layers of the human eye,
we performed immunofluorescence on formalin-fixed paraffin-embedded section (N=3) obtained
from normal 68-year old donor’s cadaver eyes with a commercially available antibody, antiPPP1R13L (Cat# 51141-1-AP, Proteintech, IL, USA). Antigen retrieval was performed in 1X
citrate buffer (Life Technologies) warmed to 95°C for 30 minutes. Sections were allowed to cool to
room temperature and subsequently blocked in 10% normal goat serum with 1% bovine serum
albumin in 1X TBS buffer for one hour. The retinal distribution of PPP1R13L protein was
visualized by incubating the retinal section with rabbit polyclonal anti-PPP1R13L antibody at
1:300 dilution overnight at 4°C, followed by chicken anti-rabbit IgG conjugated with Alexa Fluor
594 (Cat# A21442, Life Technologies, Carlsbad, CA) at 1:3000 dilution. Nuclei were stained with
the use of Vectashield DAPI in the mounting media. The images were captured using a Zeiss
Imager Z1 fluorescence microscope equipped with AxioVS40 software version 4.8.1.0.

4.3.13. Human iPSC-RGC cultures
The human iPSCs were generated from keratinocytes or blood cells via polycistronic
lentiviral transduction (Human STEMCCA Cre-Excisable constitutive polycistronic [OKS/L-Myc]
59

Lentivirus Reprogramming Kit, Millipore) and characterized with a hES/iPS cell pluripotency RTPCR kit.
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The induced pluripotent stem cell-derived retinal ganglion cells (iPSC-RGCs) for our

studies were derived using small molecules to inhibit BMP, TGF-beta (SMAD) and Wnt signaling
to differentiate retinal ganglion cells (RGCs) from iPSCs. The iPSCs were differentiated into pure
iPSC-RGCs with structural and functional features characteristic of native RGC cells based on a
previous protocol.
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4.3.14. Evaluating oxidative stress in iPSC-RGCs
Induced pluripotent stem cell-derived retinal ganglion cells (iPSC-RGCs) were incubated
with increasing amounts of H2O2 overnight before replacing the cultures with complete media.
The cells were collected 24 hours after the H2O2 treatment, and levels of PPP1R13L transcripts
were assessed using quantitative RT-PCR and gene expression primers, Fwd-5’TGCCCCAATTCTGGAGTAGG-3’ and Rev-5’- CGGCACGTGGACACAGATT-3’ following
previously established protocols.
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Mean expression levels (±standard error of mean) were

calculated by analyzing at least three independent samples with replica reactions and presented
on an arbitrary scale that represents the expression over the housekeeping gene ACTB. Relative
gene expression was quantified using the comparative Ct method. The relative gene expression
was compared against no treatment control to obtain normalized gene expression. A two-tailed
unpaired Student’s t test was used for statistical analysis.

4.3.15. Single-cell RNA-seq of human pancreatic islets in type 1 diabetes and control subjects
Pancreatic islets were procured from the HPAP consortium under Human Islet Research
Network (https://hirnetwork.org/) with approval from the University of Florida Institutional Review
Board (IRB # 201600029) and the United Network for Organ Sharing (UNOS). A legal
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representative for each donor provided informed consent prior to organ retrieval. For type 1
diabetes (T1D) diagnosis, medical charts were reviewed and C-peptide was measured in
accordance with the American Diabetes Association guidelines, leading to five individuals with
T1D and six control individuals. T1D individuals were 50% female, and had a median age of 29.5
and median BMI of 21.25. Control individuals were 60% female, and had a median age of 13 and
median BMI of 17.3. All individuals were of Caucasian race. Organs were recovered and
processed as previously described.
cells as previously described.
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Pancreatic islets were cultured and dissociated into single

Total dissociated cells were used for single-cell capture for each

of the donors.
The Single Cell 3’ Reagent Kit v2 or v3 was used for generating scRNA-seq data. 3,000
cells were targeted for recovery per donor. All libraries were validated for quality and size
distribution using a BioAnalyzer 2100 (Agilent) and quantified using Kapa (Illumina). For samples
prepared using The Single Cell 3’ Reagent Kit v2, the following chemistry was performed on an
Illumina HiSeq4000: Read 1: 26 cycles, i7 Index: 8 cycles, i5 index: 0 cycles, and Read 2: 98
cycles. For samples prepared using The Single Cell 3’ Reagent Kit v3, the following chemistry
was performed on an Illumina HiSeq 4000: Read 1: 28 cycles, i7 Index: 8 cycles, i5 index: 0
cycles, and Read 2: 91 cycles. Cell Ranger 2.1.0 (10x Genomics) was used for bcl2fastq
conversion using the command “cellranger mkfastq --id= --run= --csv= --localmem=64 -localcores=30”. Cell Ranger 2.1.0 was used for aligning, filtering, counting, and cell calling with
the command “cellranger count --id= --transcriptome= --fastqs= --localmem=64 --localcores=35”.
Samples were aggregated using Cell Ranger 2.1.0 using the command “cellranger aggr --id= -csv=”.
Seurat 3.0.2 (http://satijalab.org/seurat/)
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was used for filtering, UMAP generation, and

initial clustering. Genes were kept that were in 0.01% of cells (3 cells), resulting in 74% of genes
remaining for analysis (24,986 of 33,694 genes). Cells with at least 200 genes were kept;
however, all cells had at least 200 genes, so this filtering didn’t eliminate any of the 35,134 cells.
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nFeature, nCount, percent.mt, nFeature vs nCount, and percent.mt vs nCount plots were
generated to ascertain the lenient filtering criteria of 200 > nFeature < 7,500, percent.mt < 30,
and nCount <100,000, which led to the filtering out of 66 cells (35,066 cells remaining). Data was
then log-normalized, and the top 2,000 variable genes were detected using the “vst” selection
method. The data was then linearly transformed, and PCA was carried out on the scaled data,
using the 2,000 variable genes as input. To determine the dimensionality of the data (i.e. how
many principal components to choose when clustering), we employed two approaches: (1) a
Jackstraw-inspired resampling test that compares the distribution of p values of each PC against
a null distribution and (2) an elbow plot that displays the standard deviation explained by each
principal component. Based on these two approaches, 14 PCs with a resolution of 2 was used to
cluster the cells, and non-linear dimensionality reduction (UMAP) was used with 14 PCs to
visualize the dataset.
DoubletFinder 2.0
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was used to demarcate and remove potential doublets in the data as

previously described, with the following details: paramSweep_v3 was used, doubletFinder_v3
was used, 14 PCs were used for pK identification (no ground-truth), and the following parameters
were used when running doubletFinder_v3: PCs = 14, pN = 0.25, pK =0.005, nExp = nEx_poi.adj,
sct = FALSE. The doublets had higher nCount than the singlets identified using this method, and
the 807 doublets were removed from further analyses.
Following doublet removal, the raw data for the remaining 34,259 cells was log
normalized, the top 2,000 variable genes were detected, the data underwent linear
transformation, and PCA was carried out, as described above. Both the Jackstraw-inspired
resampling test and an elbow plot of standard deviation explained by each principal component
were used to determine the optimal dimensionality of the data, as described above. Based on
these two approaches, 11 PCs with a resolution of 1.2 was used to cluster the cells, and UMAP
was used with 11 PCs to visualize the 28 clusters detected.
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Garnett was used for initial cell classification as previously described.

In brief, a cell

type marker file with 17 different cell types was compiled using various resources,

80,81,84

and this

marker file was checked for specificity using the “check_markers” function in Garnett by checking
the ambiguity score and the relative number of cells for each cell type. A classifier was then
trained using the marker file, with “num_unknown” set to 150, and this classifier was then used to
classify cells and cell type assignments were extended to nearby cells, “clustering-extended type”
(Louvain clustering).
TooManyCells 2.0.0.0 was then used to cluster and visualize the 34,259 single cells, as
previously described.
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Briefly, the raw data from the 34,259 cells were not filtered and were

normalized by total count and gene normalization by median count followed by frequency-inverse
document frequency (tf-idf) using the flags --normalization "BothNorm and --no-filter. The
“clustering-extended type” cell labels from Garnett, as well as the demarcation of canonical cell
markers, were used to identify broad classes of cell types found within the pancreas, of which we
focused on four: Beta, Stellate, Endothelial, and Immune cells.
Differential genes were found using edgeR 3.24.3 through TooManyCells with the
normalization “NoneNorm” to invoke edgeR single cell preprocessing, including normalization and
filtering. Briefly, edgeR fits normalized expression data to a negative binomial model and uses an
exact test with false discovery rate (FDR) control to determine differential expressed genes.
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4.3.16. Single-cell RNA-seq of mouse aorta
All animal experiments were performed following protocols approved by the Institutional
Animal Care and Use Committee at Baylor College of Medicine in accordance with the guidelines
of the National Institutes of Health. The Center for Comparative Medicine at Baylor College of
Medicine monitors the environmental conditions in the animal husbandry rooms. All mice housed
2

in standard ventilated cages, floor area 65 in , maximum 4 mice per cage. Room temperatures
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are maintained at 70˚F ± 2˚. Normal humidity for animal holding rooms ranges from 30% to 70%.
The standard light timer is set on a 14-hour light cycle with the lights coming on at 6 AM and off at
8 PM.
Ascending aortic samples were harvested from Mef2c-Cre ROSA26RmT/mG male mice
(N=5) and were pooled in Hanks’ Balanced Salt Solution (HBSS, #14175095, Thermo Fisher
Scientific) with 10% fetal bovine serum. Extra aortic tissues were removed and the aortic tissues
were cut into small pieces. To digest the aortas, samples were subsequently incubated with an
enzyme cocktail (3 mg/ml collagenase type II (LS004176, Worthington); 0.15 mg/ml collagenase
type XI (C7657, Sigma-Aldrich); 0.24 mg/ml hyaluronidase type I (H3506, Sigma-Aldrich); 0.1875
mg/ml elastase (LS002290, Worthington); 2.38 mg/ml HEPES (H4034, Sigma-Aldrich)) in Ca/Mg
contained-HBSS (#14025092, Thermo Fisher Scientific) for 60 minutes at 37 °C. The cell
suspension was filtered through a 40 μm cell strainer (CLS431750-50EA, Sigma-Aldrich),
centrifuged at 300 g for 10 minutes, and resuspended using cold HBSS (#14175095) with 5%
fetal bovine serum. Cells were stained with DIPI and were sorted to select viable cells (≥ 95%
viability) by flow cytometry (FACS Aria III, BD Biosciences).
The cells were dispensed onto the Chromium Controller (10x Genomics) and indexed
single cell libraries were constructed by a Chromium Single Cell 3’ v2 Reagent Kit (10x
Genomics). cDNA libraries were then sequenced in a pair-end fashion on an Illumina NovaSeq
6000. Raw FASTQ data was aligned by Cell Ranger 3.0 with GRCh38. Mapped unique molecular
identifier (UMI) counts were imported into Seurat 3.1.4 and built into Seurat objects using the
“CreateSeuratObject” function. Cells expressing less than 200 or more than 5000 genes were
filtered out for exclusion of non-cell or cell aggregates. Cells with more than 10% mitochondrial
genes were also excluded. Data was then normalized and processed into scaled data. Principal
component analysis (PCA) and non-linear dimensional reduction using t-Distributed Stochastic
Neighbor Embedding (t-SNE) were performed to create clusters and those visualization. The
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“FindAllMarkers” function in Seurat was used to identify the conserved marker genes in each
cluster.

4.3.17. Single-cell RNA-seq of human aorta
The protocol for collecting human aortic tissue samples for scRNA-seq study was
approved by the Institutional Review Board at Baylor College of Medicine. Written informed
consent was provided by all participants before enrollment. All experiments conducted with
human tissue samples were performed in accordance with the relevant guidelines and
regulations. Ascending aortic samples were acquired from 3 controls (2 female and 1 male, heart
transplant recipient or lung transplant donor) and 8 individuals with ascending thoracic aortic
aneurysm (4 female and 4 male). Additional information can be found in the Life Sciences
2

Reporting Summary of this study. For each sample, a piece of aortic tissue (1-2 cm ) was torn
into thin layers and cut into small pieces in Hanks’ balanced salt solution (HBSS, without Ca

2+

2+

and Mg ) (Gibco, Waltham, MA, USA) with 10% fetal bovine serum (FBS). Small pieces of tissue
were then moved to enzyme cocktail prepared with 3 mg/ml collagenase type II (LS004176,
Worthington Biochemical Corp., Lakewood, NJ, USA), 0.15 mg/ml collagenase type XI (H3506,
Sigma Corp., Kanagawa, Japan), 0.25 mg/ml soybean trypsin inhibitor (LS003571, Worthington),
0.1875 mg/ml elastase lyophilized (LS002292, Worthington), 0.24 mg/ml hyaluronidase type I
(H3506, Sigma), and 2.38 mg/ml 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES,
H4034, Sigma) in HBSS (with Ca

2+

2+

and Mg ) (14025092, Thermo Fisher Scientific, Waltham,

MA, USA) and were digested in a 37˚C water bath for 1 to 2 hours. Tissue dissociation was
examined under a microscope. Cell suspensions were collected by using a 40-µm cell strainer
(CLS431750-50EA, Corning, Inc., Corning, NY, USA), centrifuged at 300 g for 10 minutes, and
resuspended in HBSS (without Ca

2+

2+

and Mg ) (14175095, Thermo Fisher) with 5% FBS,

followed with incubation on ice for 30 minutes. Cells were then stained by using a live and dead
cell kit (L3224, Thermo Fisher) and were submitted for flow cytometry (BD) for the collection of
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live singlet cells. The living cell rate was further examined under a microscope by using trypan
blue (T8154, Sigma Corp., Kanagawa, Japan) staining.
Single-cell suspensions were submitted to the 10X Genomics Chromium System (10x
Genomics, Pleasanton, CA, USA), followed by the construction of 3’ gene expression v3 libraries
and sequencing on an Illumina NovaSeq 6000. Raw FASTQ data alignment was processed by
using Cell Ranger 3.0, with GRCh38 as a reference. Mapped unique molecular identifier (UMI)
counts were loaded to R for further analysis. The single-cell sequencing data were filtered by
using Seurat 3.0 with the following criteria: gene count per cell >200 and <4000 (or 5000),
percentage of mitochondrial genes <10%, and no HBB gene detected in the cell. Data were then
normalized and processed into scale data, linear dimensional reduction, cluster finding, and
nonlinear dimensional reduction for visualization according to the Seurat manual. To identify
clusters in multiple combined datasets, we performed additional integration after normalization
and before scale. The conserved (marker) genes for each cluster were identified by using the
function “FindAllMarkers” in Seurat. For reclustering, the UMI count of cells of interest were
extracted and analyzed similarly to clusters identified in multiple combined datasets.

4.4. Results and Discussion
4.4.1. Discovery: ExoPheWAS in PMBB
We interrogated a dataset of 10,900 individuals with WES data in PMBB (Table 4.1) for
carriers of rare (MAF ≤ 0.1% in gnomAD) pLOF variants, which include frameshift insertions or
deletions, gain or loss of stop codon, and disruption of canonical splice site dinucleotides. The
distribution of the number of carriers for rare pLOF variants per gene was on a negative
exponential distribution (Appendix C, Figure S1). We chose to interrogate genes with at least 25
heterozygous carriers for rare pLOFs (N=1,518 genes), for which we show that statistical power
to detect association is sufficient as a function of effect size and the associated phenotype’s
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number of cases (Appendix C, Figure S2). We collapsed rare pLOF variants into gene burdens
across these 1518 genes for ExoPheWAS analyses with 1000 binary phecodes with at least 20
cases (Figure 4.1). Given that p values for gene burden association studies interrogating rare
loss-of-function variants may be inflated due to their higher likelihood of increasing disease risk
compared to other variants,
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we found that our associations roughly deviated from the fitted

expected distribution at an observed p<E-06 (Appendix C, Figure S3). We identified 97 gene
burdens with phenotype associations at p<E-06 (Figure 4.2; Appendix C, Table S1). We
addressed potential inflation issues regarding small sample sizes by using Firth’s penalized
likelihood approach, and found that beta and significance estimates were consistent with exact
logistic regression (Appendix C, Table S1).

Basic demographics
N

10900

Female, N (%)

4432 (40.7)

Median Age (at biobank entry), yr

67.0

Genetically informed ancestry
AFR, N (%)

2172 (19.9)

AMR, N (%)

304 (2.8)

EAS, N (%)

79 (0.7)

EUR, N (%)

8198 (75.2)

SAS, N (%)

114 (1.0)

Cardiovascular phenotypes
Essential hypertension, N (%)

6441 (59.1)

Ischemic Heart Disease, N (%)

5008 (45.9)

Myocardial infarction, N (%)

1640 (15.0)

Cardiomyopathy, N (%)

1976 (18.1)

Congestive heart failure; nonhypertensive, N (%)

3695 (33.9)

Heart transplant/surgery, N (%)

518 (4.8)

Cardiac dysrhythmias, N (%)

5784 (53.1)

Atrial fibrillation and flutter, N (%)

3782 (34.7)

Cerebrovascular disease, N (%)

1706 (15.7)

Peripheral vascular disease, N (%)

954 (8.8)

Aortic aneurysm, N (%)

836 (7.7)

Atherosclerosis, N (%)

539 (4.9)
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Endocrine/metabolic phenotypes
Type 2 diabetes, N (%)

2799 (25.7)

Overweight, obesity and other hyperalimentation, N (%)

2275 (20.9)

Hyperlipidemia, N (%)

6231 (57.2)

Hypercholesterolemia, N (%)

2034 (18.7)

Hypothyroidism, N (%)

1314 (12.1)

Gout and other crystal arthropathies, N (%)

811 (7.4)

Gastrointenstinal phenotypes
Esophagitis, GERD and related diseases, N (%)

2526 (23.2)

Gastrointestinal hemorrhage, N (%)

660 (6.1)

Diverticulosis and diverticulitis, N (%)

610 (5.6)

Chronic liver disease and cirrhosis, N (%)

449 (4.1)

Renal phenotypes
Chronic renal failure (CKD), N (%)

2135 (19.6)

End stage renal disease, N (%)

510 (4.7)

Kidney replaced by transplant, N (%)

283 (2.6)

Neuropsychiatric phenotypes
Mood disorders, N (%)

1353 (12.4)

Anxiety, phobic and dissociative disorders, N (%)

1322 (12.1)

Delirium dementia and amnestic and other cognitive disorders, N (%)

123 (1.1)

Respiratory phenotypes
Chronic airway obstruction, N (%)

1314 (12.1)

Asthma, N (%)

920 (8.4)

Obstructive sleep apnea, N (%)

1623 (14.9)

Respiratory failure, insufficiency, arrest, N (%)

697 (6.4)

Sensory phenotypes
Cataract, N (%)

796 (7.3)

Hearing loss, N (%)

579 (5.3)

Glaucoma, N (%)

449 (4.1)

Congenital phenotypes
Cardiac and circulatory congenital anomalies, N (%)

780 (7.2)

Genitourinary congenital anomalies, N (%)

151 (1.4)

Cystic kidney disease, N (%)

108 (1.0)

Congenital anomalies of great vessels, N (%)

77 (0.7)

Table 4.1. Demographics and disease prevalence of the PMBB discovery cohort. Demographic
information and clinical phenotypic counts for all individuals with whole-exome sequencing linked to
electronic health records in the Penn Medicine BioBank (PMBB). Clinical phenotypes were defined by
phecodes (see Materials and Methods). Data is represented as count data with percent prevalence in the
population in parentheses, where appropriate.
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Figure 4.1. Flow chart for exome-by-phenome-wide association analysis using electronic health
record phenotypes. Flow chart diagram outlining the primary methodologies used for conducting the
exome-by-phenome-wide association study and for evaluation of the robustness of the associations,
indicating that 97 genes had associations at a significance level of p<E-06 via logistic regression. The
pathways starting with short descending arrows represent the discovery phase, in which predicted loss-offunction (pLOF)-based gene burdens were studied on an exome-by-phenome-wide scale in 10,900
individuals from the Penn Medicine BioBank (PMBB). “Replication studies in PMBB” refers to analyses of
gene-phenotype associations using REVEL-informed missense-based gene burdens and univariate
analyses within the discovery PMBB cohort, as well as in an independent cohort of African Americans in the
PMBB (the PMBB2 cohort; N=6,432). Additional replication studies included analyses of gene-phenotype
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associations using pLOF-based gene burdens, REVEL-informed missense-based gene burdens, and
univariate analyses in BioMe (N=23,989), DiscovEHR (N=85,450), and the UK Biobank (N=32,268), as well
as univariate analyses in BioVU (N=66,400).

Figure 4.2. ExoPheWAS plot exhibits the landscape of gene-phenotype associations across the
exome and phenome in the Penn Medicine BioBank. Plot of the results of the exome-by-phenome-wide
association study (ExoPheWAS) in the Penn Medicine BioBank for 1518 gene burdens of rare (MAF ≤ 0.1%)
predicted loss-of-function (pLOF) variants. The x-axis represents the exome and is organized by
chromosomal location. The location of each gene along the x-axis is according to the gene’s genomic
location per Genome Reference Consortium Human Build 37 (GRCh37). The association of each gene
burden with a set of 1,000 phecodes is plotted vertically above each gene, with the height of each point
representing the –log10(p value) of the association between the gene burden and phecode using a logistic
regression model. Each phecode point is color-coded according to the phecode group, and the directionality
of each triangular point represents the direction of effect (DOE). The blue line represents the significance
threshold at p=E-06 to account for multiple hypothesis testing.

4.4.2. Replication in PMBB, other medical biobanks, and UK Biobank
We evaluated the robustness of the significant gene-phenotype associations identified via
our pLOF-based ExoPheWAS analyses by testing the associations in the same PMBB cohort
between a separate group of rare likely deleterious exonic missense variants in the 97 significant
genes with the same disease phenotypes that were identified in discovery (Figure 4.1). We
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utilized REVEL, an ensemble method for predicting the pathogenicity of missense variants,

20

to

define predicted deleterious missense (pDM) variants (REVEL score ≥ 0.5) given the tool’s
success in identifying likely pathogenic variants for gene burden association studies.

10

First, we

separately collapsed rare (MAF ≤ 0.1%), REVEL-informed pDM variants to test discovery-driven
associations with their corresponding phenotypes (Appendix C, Table S2). We also interrogated
single variants, including both pLOF variants and pDM (REVEL ≥ 0.5) variants, in the 97 genes
identified in discovery that were of sufficient frequency (MAF > 0.1%) and therefore were not
included in either of the gene burden analyses (Appendix C, Table S3).
We also endeavored to replicate our significant ExoPheWAS discovery analysis
associations (Figure 4.1) using a separate cohort of 6,432 African Americans in PMBB who were
exome-sequenced (PMBB2; Appendix C, Table S4-6), as well as two additional medical biobanks
with WES linked to EHR phenotypes, namely BioMe (Mount Sinai; Appendix C, Table S7-9) and
DiscovEHR (Geisinger Health System; Appendix C, Table S10-12), and the population-based UK
Biobank (UKB) (Appendix C, Table S13-15). For each of the 97 significant genes, we
interrogated: 1) gene burdens after collapsing rare (MAF ≤ 0.1%) pLOF variants, 2) gene burdens
after collapsing non-overlapping rare (MAF ≤ 0.1%) REVEL-informed pDM variants, and 3) single
pLOF or REVEL-informed pDM variants with MAF > 0.1% for association with their discovery
phenotypes. Finally, we further interrogated a targeted list of univariate replications in BioVU
(Vanderbilt; Appendix C, Table S16).

4.4.3. Positive control gene-phenotype associations
We identified a total of 26 robust genes using a Diverse Convergent Evidence (DiCE)
approach
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for ranking associations using a combination of the number of significant replications

and functional validation (Table 4.2; Appendix C, Table S17). Five of these genes can be
considered positive control gene-disease associations. A gene burden of rare pLOFs in CFTR
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was significantly associated with cystic fibrosis (CF), a recessive condition caused by biallelic
variants in CFTR. This was driven by individuals with a rare pLOF who had a second deleterious
CFTR variant—predominantly ∆F508—that was not included in the pLOF gene burden. This
association of the CFTR pLOF gene burden with CF was not replicated in other biobanks due to
the extremely low case prevalence of CF (Appendix C, Table S18). The CFTR pLOF gene burden
was also significantly associated with bronchiectasis independent of a CF diagnosis and occurred
in individuals without a second CFTR variant; this finding replicated in all interrogated cohorts.
While a predisposition to bronchiectasis due to haploinsufficiency of CFTR has been suggested,
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our finding strengthens this observation. TTN is a known dilated cardiomyopathy gene that
replicated convincingly across other cohorts. MYBPC3 is a known hypertrophic cardiomyopathy
(HCM) gene that replicated in BioMe and DiscovEHR, but not in UKB, where HCM had a casecontrol ratio of an order of magnitude lower than the medical biobanks (Appendix C, Table S18).
These results indicate that medical biobanks have a different—and sicker—population that
enables discovery of associations of human diseases driven by rare genetic variants. A pLOF
gene burden in BRCA2 was associated with breast cancer and replicated in all biobanks. BRCA1
was associated with breast cancer in discovery (p=1.29E-04) but due to power did not meet our
significance threshold. Finally, CYP2D6 is a P450 enzyme known to metabolize opioids;
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we

found that CYP2D6 was significantly associated with adverse effects of therapeutic opiate use.
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Gene

Phecode Description

Discovery
P

Replications
(N)

Clinical and/or
Experimental
Evidence

BRCA2

Breast cancer

1.72E-07

4

a

CFTR

Bronchiectasis

2.27E-07

10

a

Pseudomonal pneumonia

4.21E-11

5

a

1.05E-15

1

a

1.50E-09

3

a

MYBPC3

Cystic fibrosis
Opiates and related narcotics causing
adverse effects in therapeutic use
Hypertrophic cardiomyopathy

3.49E-15

5

a

TTN

Cardiomyopathy

7.83E-13

10

a

Cardiac conduction disorders

6.45E-09

10

a

Cardiac dysrhythmias

1.77E-08

12

a

7.26E-08

2

1.54E-07

3

2.89E-08

1

CYP2D6

BBS10

Benign neoplasm of brain, cranial nerves,
meninges
Abnormal results of function study of
pulmonary system
Hypertrophic cardiomyopathy

CES5A

Abnormal coagulation profile

8.10E-08

5

CILP

Aortic ectasia

4.29E-08

3

CTC1

Temporomandibular joint disorders

3.76E-07

3

DNAH6

Lack of coordination

7.93E-10

2

DNHD1

Aseptic necrosis of bone

2.67E-07

4

EFCAB5

3.19E-08

3

9.19E-08

3

FER1L6

Prolapse of vaginal walls
Phlebitis and thrombophlebitis of lower
extremities
Muscular wasting and disuse atrophy

7.18E-07

3

FLG2

Stiffness of joint

1.76E-07

2

MYCBP2

Spasm of muscle

2.08E-07

2

a

PPP1R13L

Primary open angle glaucoma

7.29E-07

2

a

RGS12

Type 1 diabetes

6.48E-08

5

a

RTKN2

Orthostatic hypotension

7.24E-07

5

SCNN1D

Cardiac conduction disorders

4.52E-07

5

TGM6

Lipoma

2.77E-07

4

TRDN

Acquired toe deformities

3.90E-07

3

WDR87

Ventral hernia

1.70E-07

4

ZNF175

Tinnitus

3.24E-10

3

ZNF334

Microscopic hematuria

1.69E-07

3

ABCA10

EPPK1
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a

a

a

a

Table 4.2. List of robust exome-by-phenome-wide significant gene-phenotype associations. List of
genes among 97 pLOF-based gene burdens with phenotype associations at p<E-06 in the Penn Medicine
BioBank (PMBB) discovery cohort that were most robust according to a Diverse Convergent Evidence
(DiCE) approach, which integrates successful replication of the association with clinical and experimental
evidence. For replication studies, gene-phenotype associations were evaluated for their robustness by
interrogating REVEL-informed missense-based gene burdens and single variants in the same discovery
PMBB cohort, and pLOF-based gene burdens, REVEL-informed missense-based gene burdens, and single
variants in an independent cohort of African Americans in PMBB (the PMBB2 cohort) as well as in BioMe,
DiscovEHR, and the UK Biobank (UKB). Targeted single variants that showed successful replication in
PMBB, PMBB2, and UKB were additionally analyzed in BioVU. Each gene-phecode association is labeled
with the corresponding p value from logistic regression analyses in the discovery phase in PMBB as well as
the number of total replications and existence of clinical/experimental evidence, as fully detailed in Appendix
C, Table S17. Only associations with at least two total checkmarks in Appendix C, Table S17, where each
successful mode of replication in a particular biobank (e.g. pLOF burden in BioMe) or the existence of
clinical/experimental evidence is labeled with a checkmark, were deemed robust and were included in this
table. Previously known associations were considered to represent positive controls and are listed at the top
of the table, and are separated from novel associations by a double line. Positive control and novel
associations are each ranked alphabetically by gene name.

4.4.4. Novel gene-phenotype associations
We identified 20 robust genes with novel disease associations that had at least two
additional replications beyond the discovery experiment, and one strongly supported by the DiCE
analysis (Table 4.2; Appendix C, Tables S2-S17). Some have prior biological plausibility, and for
others we generated additional functional data supporting a biological basis to these associations.
For example, a BBS10 gene burden was significantly associated with HCM. BBS10 is one of at
least 19 genes implicated in autosomal recessive Bardet-Biedl Syndrome and accounts for ~20%
of all cases.
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BBS10 is expressed in the heart

66

and cardiac abnormalities have been reported in

Bardet-Biedl Syndrome, including hypertrophy of the interventricular septum,

92

but cardiac

abnormalities due to haploinsufficiency of BBS10 have not been described. We interrogated
echocardiography data in carriers of rare pLOF variants in BBS10 in PMBB compared with noncarriers and found increased left ventricular outflow tract (LVOT) stroke volume, consistent with
cardiac hypertrophy (Appendix C, Table S19). Rare pLOF variants in SCNN1D, which encodes
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the delta subunit of the epithelial sodium channel (δENaC), were associated with cardiac
conduction disorders and replicated robustly across medical biobanks. SCNN1D is expressed in
the heart (unlike epithelial tissue-specific expression for SCNN1A and SCNN1B),
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there is an

association between 1p36 deletions (which contains SCNN1D) and congenital heart defects,
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and decreased expression of δENaC may contribute to disrupted Na+ and K+ homeostasis in
ischemic heart diseases.
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The association between rare pLOFs in ZNF175 and tinnitus

(additionally, hearing loss barely missed our significance threshold), which replicated in BioMe,
DiscovEHR, and UKB, is supported by the finding that mice with loss-of-function in Zfp719 (the
mouse ortholog) are profoundly deaf and have abnormal Preyer reflex (auditory startle
response)

96

as well as raised auditory brainstem response thresholds.

inner and outer hair cells of the mouse ear,

98

97

Zfp719 is expressed in

and human ZNF175 has a suggested role in

neurotrophin production and neuronal survival.
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Rare pLOFs in FER1L6 were robustly associated with muscular wasting and disuse
atrophy. FER1L6 is a member of the ferlin family of genes, and mutations in FER1L1 (dysferlin)
are known to cause recessive forms of muscular dystrophy.
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Importantly, loss of the zebrafish

ortholog Fer1l6 has been shown to lead to deformation of striated muscle and delayed cardiac
development.
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Similarly, pLOFs in MYCBP2, an E3 ubiquitin-protein ligase critical in

neuromuscular development in mice,

102

Drosophila,

103

and C. elegans,

104

were associated with

muscular spasms and dystrophy. Mice lacking the mouse ortholog Phr1 are lethal at birth without
taking a breath due to incomplete innervation of the diaphragm by markedly narrower phrenic
nerves that contain fewer axons than controls.
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We found that MYCBP2 showed significantly

decreased expression in various lower extremity muscle tissues in tibial muscular dystrophy in
humans (Appendix C, Figure S4). Our findings suggest that haploinsufficiency in FER1L6 or
MYCBP2 increases the risk of developing dystrophic skeletal muscle.
Rare pLOFs in CES5A were robustly associated with abnormal coagulation. Upon further
investigation of EHR lab data in PMBB, we found that carriers of rare pLOF variants in CES5A
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had increased international normalized ratios (INR; ß=8.2, p=2.13E-02, N=5,275) and partial
thromboplastin times (PTT; ß=13.9, p=2.07E-02, N=3,786) compared to non-carriers. Through
chart review, we found an enrichment of gastrointestinal bleeding episodes following use of antiplatelet medications among carriers for rare pLOF variants in CES5A. CES5A is part of the family
of carboxylesterases, which are known metabolizers of various orally bioavailable drugs,
including the anti-platelet medications aspirin and clopidogrel.
expression in the liver,
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Given its predominant

it is thus plausible that haploinsufficiency of CES5A predisposes to

adverse effects of anti-platelet medications.
Another novel finding was that rare pLOF variants in PPP1R13L, one of the most
evolutionarily conserved inhibitors of p53,

106

were associated with primary open angle

glaucoma—a disease of the optic nerve head (ONH) that causes progressive vision loss. We
interrogated the expression of PPP1R13L in silico using the Ocular Tissue Database (OTDB) and
found that it is highly expressed in ocular tissues, with optic nerve and the ONH among the
highest (Appendix C, Table S20). Retinal ganglion cells (RGCs) are the primary cells affected by
glaucoma, and cells in the ONH such as astroglia, microglia, and endothelial cells mediate RGC
degeneration in response to stress such as increased intraocular pressure. We investigated
whether Ppp1r13l is differentially expressed in the mouse ONH in glaucoma by comparing
microarray gene expression datasets of the ONH.
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We found Ppp1r13l expression to be highest

during late-early to moderate stages of glaucoma (Appendix C, Figure S5A). Additionally,
inhibition of PPP1R13L has been shown to exacerbate retinal ganglion cell (RGC) death following
axonal injury.
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We found that the PPP1R13L protein is predominantly localized to the ganglion

cell layer in the adult human retina with some expression in the outer and inner plexiform layers,
confirming its role in RGC function (Appendix C, Figure S5B). Using human induced pluripotent
stem cell-derived RGCs (iPSC-RGCs), we found that oxidative stress markedly upregulated
PPP1R13L expression (Appendix C, Figure S5C) to a much greater extent than even superoxide
dismutase 1 (SOD1), which is known to be transcriptionally upregulated in response to oxidative
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stress. Thus, PPP1R13L is expressed in RGCs, is significantly upregulated by oxidative stress,
and may help to prevent RGC death from p53 activation and p53-mediated apoptosis in primary
open angle glaucoma.
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Our results are consistent with the concept that haploinsufficiency of

PPP1R13L in RGCs increases the visual consequences of primary open angle glaucoma.
Another interesting novel finding was that rare pLOF variants in RGS12 were associated
with type 1 diabetes mellitus and its complications. In PMBB, carriers of rare pLOFs in RGS12
had higher median values for random serum glucose than non-carriers (ß=16.9, p=2.91E-02,
N=5,389). RGS12, an inhibitor of signal transduction in G protein signaling, contains an N
terminus PDZ domain which selectively binds to and represses the macrophage IL-8 receptor
CXCR2.
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Activation of macrophage CXCR2 by IL-8 is pro-inflammatory, and its antagonism

leads to attenuation of immune cell infiltration and cytokine release as well as a shift of
macrophages to the anti-inflammatory M2 state, thereby counteracting inflammatory signal
pathways in diabetes.
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To further investigate RGS12 in type 1 diabetes, we generated single-

cell RNA-seq data in human pancreatic islets from type 1 diabetes and control subjects collected
by the Human Pancreas Analysis Program (HPAP; https://hpap.pmacs.upenn.edu) and
interrogated RGS12 expression in distinct functional cells. We found that while RGS12 showed
no significant differential expression in pancreatic endocrine or exocrine cells in type 1 diabetes
versus control, there was a substantial reduction of expression of RGS12 in peri-islet CD45+
macrophages in type 1 diabetes (Appendix C, Figure S6). These results are consistent with a
model that RGS12 dampens islet macrophage inflammatory responses and that
haploinsufficiency of RGS12 predisposes to greater islet inflammation and higher risk of type 1
diabetes.
Additionally, rare pLOF variants in CILP were associated with aortic ectasia, or dilatation
of the aorta often associated with connective tissue disorders. Chart review of CILP pLOF carriers
showed an enrichment for ascending thoracic aortic aneurysms. CILP encodes an extracellular
matrix protein and is best known for its expression in chondrocytes.
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However, CILP is also
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expressed in the cardiovascular system, and has been shown to be involved in cardiac
113

remodeling in response to pressure overload.

We performed single-cell RNA-seq of normal

mouse aorta and found that Cilp expression was localized mainly to adventitial fibroblasts in the
aorta, but showed no significant expression in aortic smooth muscle cells (Appendix C, Figure
S7A-B). Single-cell RNA-seq of human aorta confirmed that CILP is localized to aortic fibroblasts
(Appendix C, Figure S7C-D). Importantly, CILP has been reported to modulate TGFB1 signaling
and IGF1-induced proliferation,
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and dysregulated TGF-ß signaling has been shown to

contribute to the pathogenesis of thoracic aortic aneurysm formation.
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To further interrogate the

relationship between CILP and TGFB1 in human fibroblasts, we conducted a meta-analysis of 11
independent microarray and RNA-seq datasets for human fibroblasts from various tissues treated
with TGF-ß from the Gene Expression Omnibus (GEO). We found that CILP was in the top 1% of
significantly upregulated genes in human fibroblasts when treated with TGF-ß (log2 fold change =
1.964, p = 3.60E-29; Appendix C, Figure S7E), confirming its role in a functional feedback loop
with TGF-ß as similarly seen in the context of chondrocyte metabolism.
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Furthermore, CILP was

differentially co-expressed with IGF1 as well as genes implicated in aortic ectasia including
SMAD3, ACTA2, MYH11, and ELN (Appendix C, Figure S7E).
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Our findings suggest that

haploinsufficiency of CILP predisposes to the risk of developing thoracic aortic dilatation, perhaps
through compromising the structural integrity of the aortic wall and contributing to dysregulation of
TGF-ß signaling.

4.4.5. Conclusions
There has been a significant gap of knowledge regarding the clinical implications of
genetic variants overrepresented among Africans due to the lack of ancestral diversity in the
populations that have been studied in previous genetic association studies.
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Our discovery

study included 19.9% African ancestry individuals, and three of our replication cohorts included
substantial numbers of African-Americans (6,432 in PMBB2, 6,470 in BioMe, and 10,456 in
78

BioVU). Interestingly, we identified 16 rare predicted deleterious single variants which are African
ancestry-specific and that replicated associations with the same disease in which a pLOF gene
burden was associated in discovery (Appendix C, Table S21). None of these rare variants exist in
the GWAS catalog or have been previously mentioned in the published literature. Our findings
suggest that larger experiments of this type in ethnically diverse cohorts are imperative for
improving our understanding of the contribution of ancestry-specific rare genetic variants to
human disease.
A significant challenge in rare variant association studies is the difficulty of performing
replication studies. Here we show the value of evaluating the robustness of gene burden
associations by interrogating other deleterious variants in the same genes (but in different
individuals) in the same biobank cohort. We also performed replication studies in another cohort
in PMBB as well as in two other medical biobanks with WES data. These provided more
replication than the UKB, which is a population-based biobank and is widely recognized to have a
“healthy volunteer selection bias”
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and has lower prevalence of the specific diseases than the

medical biobanks (Appendix C, Table S18). This may be one factor explaining the relative lack of
novel findings in gene burden studies using UKB for discovery.
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Finally, we show that one

should not expect a uniform fit for p values when interrogating the cumulative effect of rare pLOF
variants, and that the validity of the results is due as much to robust replication in other cohorts as
to the determination of a particular significance threshold. To this end, our study emphasizes the
value of medical biobanks for discovery of novel gene-disease associations based on rare
variants.
In conclusion, we demonstrate the feasibility and value of aggregating rare pLOF variants
into gene burdens on an exome-wide scale for association with EHR-derived phenotypes in a
medical biobank for discovery of novel gene-disease relationships. Our compelling novel findings
based on initial discovery in < 11,000 whole exomes suggest that much larger experiments of this
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type are likely to be highly informative and will lead to many new insights into the biology of
human phenotypes and diseases.

80

CHAPTER 5. Exome-wide association of rare coding variants
with hepatic fat derived from CT imaging in a medical biobank

5.1. Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver
disease in Western countries and can lead to metabolic dysfunction, liver inflammation, end-stage
liver disease. While hepatic fat is a highly heritable trait, previous genetic studies of hepatic fat
quantifications derived from abdominal imaging scans have traditionally focused on common
variants and have been largely underpowered for interrogation of additional rarer genetic
variation.
Methods: We linked whole-exome sequences (WES) to hepatic fat quantifications derived from
clinical CT scans using machine learning in a subset of 10,283 individuals in the Penn Medicine
BioBank (PMBB). We conducted exome-wide discovery analyses for single variants (MAF>0.1%)
as well as for gene burdens of rare predicted loss-of-function (pLOF) variants (MAF≤0.1%) in
PMBB. We also tested a burden of rare pLOF ± predicted deleterious missense (pDM) variants
(REVEL≥0.5) for genes nominated by the single variant discovery. We performed replication in
the UK Biobank (UKB) by linking WES to MRI-based liver proton density fat fractions (PDFF).
Results: Exome-wide significant single variants confirmed previously described associations (e.g.
variants in PNPLA3, TM6SF2, SAMM50) and revealed new variants in FGD5 and CITED2
associated with hepatic fat. We also found that a gene burden of rare predicted deleterious
coding variants in certain genes nominated by single variants (e.g. PNPLA3) were associated
with hepatic fat. Additionally, a burden of rare pLOFs in LMF2 were exome-wide significant in
their association with increased hepatic fat, a finding that replicated in UKB.
Conclusion: We show the value and feasibility of conducting an exome-wide evaluation of
common and rare variants for association with hepatic fat as quantitated from abdominal CT
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scans via machine learning. Importantly, this work represents the first exome-wide association
studies for hepatic fat quantifications in a medical biobank. In addition to confirming signals for
single variants previously associated with hepatic fat, we also found new common and rare
variants associated with hepatic fat which replicated in UKB. We suggest that this approach
applied to larger ancestrally diverse populations will uncover new genetic modulators of
intrahepatic fat.

5.2. Introduction
Hepatic steatosis, or excess accumulation of intrahepatic fat, is a major risk factor for
metabolic dysfunction, liver inflammation, and end-stage liver disease accompanied by high
morbidity and mortality.
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In particular, non-alcoholic fatty liver disease (NAFLD) is the most

common cause of chronic liver disease in Western countries, and there is growing evidence that
the clinical burden of NAFLD extends beyond liver-related morbidity and mortality such as
increasing risk for type 2 diabetes mellitus, cardiovascular disease, and chronic kidney
disease.
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While NAFLD has high heritability and our understanding of the genetic underpinnings

of NAFLD has advanced, known genetic risk variants still explain only a small fraction of
heritability, suggesting the existence of additional genetic variation that may confer risk for or
protection from NAFLD which have yet to be uncovered.
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Large-scale systematic quantification of hepatic fat derived from clinical imaging to
measure the extent of hepatic steatosis has proven to be important for discovery of genetic
variants that contribute to risk of developing NAFLD.
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However, genetic studies in this realm

have traditionally focused on analysis of common variants and have been largely underpowered
for interrogation of additional rare genetic variation. The Penn Medicine BioBank (PMBB) is a
large academic medical biobank enriched for disease with genetic sequencing linked to electronic
health record (EHR) phenotypes, in which a substantial number of participants have received
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abdominal computed tomography (CT) scans in the course of routine clinical care. We automated
hepatic fat quantification derived from abdominal CT scans using a machine learning approach.
In this study, we present an exome-wide analysis of the association of rare coding variants with
hepatic fat in a subset of ~10K individuals in the PMBB for whom CT-derived hepatic fat
quantitation and whole exome sequence data were available.

5.3. Materials and Methods
5.3.1. Setting and study participants
All individuals recruited for the Penn Medicine BioBank (PMBB) are patients of clinical
practice sites of the University of Pennsylvania Health System. Appropriate consent was obtained
from each participant regarding storage of biological specimens, genetic sequencing, and access
to all available EHR data. These analyses focused on the subset of PMBB participants
(N=10,283) who had both CT-derived hepatic fat quantitation and whole exome sequence data
available (Table 5.1). This study was approved by the Institutional Review Board of the University
of Pennsylvania and complied with the principles set out in the Declaration of Helsinki.

5.3.2. Clinical data collection
For PMBB, all International Classification of Diseases Ninth Revision (ICD-9) and Tenth
Revision (ICD-10) diagnosis codes, clinical imaging and laboratory measurements were extracted
from the patients’ EHR. All ICD diagnosis codes and outpatient laboratory measurements
available up to July 2020 were extracted for PMBB participants. Non-contract abdominal CT
images available up to March 2019 were extracted for PMBB participants if available (N=14,249).
All laboratory values measured in the outpatient setting were extracted for participants from the
time of enrollment in PMBB until July 2020; all units were converted to their respective clinical
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Traditional Units. Minimum, median, and maximum measurements of each laboratory
measurement were recorded per individual for association analyses. Minimum, median, and
maximum values for hemoglobin A1C, alkaline phosphatase, ALT, AST, and triglycerides were
log-transformed to normalize their distributions.

5.3.3. Quantification of hepatic fat
In PMBB participants, hepatic fat was quantitated from abdominal CT scans using a fully
automated image curation and organ labeling technique using deep learning as previously
described.
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Hepatic fat was quantitated as the difference in mean Hounsfield Units (HU)

between the spleen and liver (spleen HU – liver HU) to create a measure that is directly
proportional to intrahepatic fat. Minimum, median, and maximum measurements of hepatic fat
were recorded per individual given the multiple independent CT scans available per patient.

5.3.4. Phenome-wide association of hepatic fat with EHR diagnoses and traits
A phenome-wide association study (PheWAS) approach was used to determine the
phenotypes associated with the quantitative trait of median hepatic fat in PMBB for the 10,283
unrelated individuals in PMBB with both exome sequences and quantitated hepatic fat
available.
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ICD-10 encounter diagnoses were mapped to ICD-9 via the Center for Medicare and

Medicaid Services 2017 General Equivalency Mappings
(https://www.cms.gov/Medicare/Coding/ICD10/2017-ICD-10-CM-and-GEMs.html) and manual
curation. Phenotypes for each individual were then determined by mapping ICD-9 codes to
distinct disease entities (i.e. Phecodes) using the R package “PheWAS”.

34

Patients were

determined to have a certain disease phenotype if they had the corresponding ICD diagnosis on
2 or more dates, while phenotypic controls consisted of individuals who never had the ICD code.
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Individuals with an ICD diagnosis on only one date as well as individuals under control exclusion
criteria based on PheWAS phenotype mapping protocols were not considered in statistical
analyses. Each Phecode was tested for association with quantitated hepatic fat using a logistic
regression model adjusted for age, sex, and PC1-10 of genetic ancestry. PheWAS analyses were
performed as trans-ancestral cosmopolitan analyses. Our association analyses considered only
disease phenotypes with at least 20 cases based on a prior simulation study for power analysis.
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This led to the interrogation of 1396 total Phecodes, and we used a Bonferroni correction to
adjust for multiple testing (p=0.05/1396=3.58E-05).

5.3.5. Whole-exome sequencing, variant annotation, and selection for association testing
This study included a subset of 43,731 individuals in the PMBB who had undergone
whole-exome sequencing (WES). We extracted DNA from stored buffy coats and then mapped
exome sequences as generated by the Regeneron Genetics Center (Tarrytown, NY) to GRCh38
as previously described. Samples with low exome sequencing coverage, high missingness (i.e.
greater than 5% of targeted bases), dissimilar reported and genetically determined sex, and
genetic evidence of sample duplication were not included in this subset. For subsequent
st

nd

phenotypic association analyses, we removed samples with evidence of 1 and 2 -degree
relatedness, leading to a total of sample size of 41,759 for analysis.
Genetic variants were annotated using ANNOVAR (version 2019Oct24)
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for information

regarding variant effect as determined by the NCBI Reference Sequence (RefSeq) database,
Rare Exonic Variant Ensemble Learner (REVEL) scores for missense variants,
frequencies reported by the Genome Aggregation (gnomAD) v2.
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20

126

and allele

Predicted loss-of-function

(pLOF) variants were defined as frameshift insertions or deletions, gain of stop codon, and
disruption of canonical splice site dinucleotides. For splicing variants, we removed those with
SpliceAI scores < 0.2 for loss or gain of acceptor or donor site.
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For single variant association

tests in the PMBB discovery, all nonsynonymous coding variants and splicing variants with minor
allele frequency (MAF) > 0.1% in Africans or non-Finnish Europeans in gnomAD were selected
for association testing. For gene burden association tests, rare (MAF ≤ 0.1% in gnomAD) pLOF
variants were aggregated per gene with or without rare missense variants with REVEL score ≥
0.5.

5.3.6. Exome-wide association studies for hepatic fat
This study focused on a subset of 10,283 unrelated individuals in PMBB with both exome
sequences and quantitated hepatic fat available. For exome-wide association studies with hepatic
fat, individuals with ICD9/10 diagnosis codes indicating chronic hepatitis B or C (B18.0-B18.2,
070.32, 070.21, 070.22, 070.23, 070.31, 070.33, 070.54) or alcohol-related conditions or
dependence, such as alcoholic liver disease (571.0, K70.0), alcoholic hepatitis (571.1, K70.1),
alcoholic fibrosis and sclerosis of the liver (571.2, K70.3), alcoholic cirrhosis of liver and/or ascites
(571.2, K70.2), alcoholic hepatic failure, coma, and unspecified alcoholic liver disease (571.3,
K70.4, K70.40, K70.41, K70.9), and alcohol dependence (303.0, 303.9, F10.229, F10.20), were
excluded (N=689), leading to total sample size of 9,594 for analyses.
Exome-wide association studies for hepatic fat were conducted in two stages, namely
single variant discovery and gene burden discovery. For the discovery analyses, single variants
and gene burdens with at least 10 total carriers with hepatic fat quantifications available were
associated with hepatic fat using a linear regression model adjusted for age, sex, and principal
components (PC) of ancestry (PC1-5 in Africans, PC1-10 in Europeans). For targeted gene
burden analyses of genes nominated by the single variant discovery, gene burdens with at least 5
total carriers with hepatic fat quantifications available were associated with hepatic fat. For all
gene burdens, we used an additive genetic model to aggregate variants as previously
described.
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These analyses were performed separately by African and European genetic
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ancestry and combined with inverse variance weighted meta-analysis. Additionally, transancestral cosmopolitan analyses were also performed, adjusted for age, sex, and cosmopolitan
PC1-10.
We conducted a PheWAS for the gene burden of pLOF variants in LMF2, where we
focused on a subset of 162 Phecodes in the “digestive” group, leading to a Bonferroni-corrected
significance threshold of p=0.05/162=3.09E-04. The gene burden PheWAS analysis was
performed separately by African and European genetic ancestry and combined with inverse
variance weighted meta-analysis.

5.3.7. Replication analyses in the UK Biobank (UKB)
Replication analyses were conducted in the UK Biobank (UKB). For replication studies in
the UKB, we focused on 9,071 individuals with both exome sequences (after removing samples
st

nd

with evidence of 1 and 2 -degree relatedness, high missingness, and dissimilar reported and
genetically determined sex) and quantitated hepatic fat available based on liver proton density fat
fraction (PDFF) derived from MRI. Individuals with ICD10 diagnosis codes indicating chronic
hepatitis B or C or alcohol-related conditions or dependence were excluded (N=22), leading to a
total sample size of 9,049 for analyses. Single variants and gene burdens with at least 5 total
carriers with hepatic fat quantifications available selected based on discovery in PMBB were
associated with hepatic fat using a linear regression model adjusted for age, sex, and PC1-10 of
ancestry. Similarly, for targeted gene burden analyses of genes nominated by the single variant
discovery in PMBB, gene burdens with at least 5 total carriers with hepatic fat quantifications
available were associated with hepatic fat in UKB. These analyses were performed in individuals
of European ancestry, accompanied by trans-ancestral cosmopolitan analyses. Liver PDFF
values from UKB were log-transformed to normalize their distribution for regression analyses. For
replication studies in the UKB, International Classification of Diseases Tenth Revision (ICD-10)
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diagnosis codes and liver PDFF values derived from abdominal MRI scans were downloaded.
Access to the UKB data for this project was from application 32133.

5.3.8. Statistical analyses
To associate hepatic fat phenotypes or genotypes with serum laboratory measurements
in PMBB, we used a linear regression model adjusted for age, sex, and PCs of genetic ancestry
(PC1-5 in Africans, PC1-10 in Europeans). These analyses were performed across all ancestries
(cosmopolitan, PC1-10) and/or separately by African and European genetic ancestry and
combined with inverse variance weighted meta-analysis. All statistical analyses, including
PheWAS and hepatic fat associations, were completed using R version 3.5 (Vienna, Austria).
Minimum, median, and maximum values for hemoglobin A1C, alkaline phosphatase, ALT, AST,
and triglycerides were log-normalized for regression analyses.

5.3.9. Analysis of publicly available expression datasets
We interrogated microarray and RNA-seq data publicly available on the NCBI GEO
platform (https://www.ncbi.nlm.nih.gov/geo/).
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We compared Lmf2 expression in liver endothelial

cells from cirrhotic livers of rats versus control (GSE1843).
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We also compared Lmf2 expression

in a hepatic steatosis mouse model due to hepatocyte-specific Sirt1 deficiency versus control
(GSE14921).
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Differential expression for each dataset was interrogated using the GEO2R

software using a moderated t statistic after log transformation was applied to the data.
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5.4. Results
5.4.1. Hepatic fat extracted from clinical CT scans is highly significantly associated with a range
of cardiometabolic diseases and traits
Among exome-sequenced individuals in PMBB (Table 5.1), we conducted a phenomewide association study (PheWAS) of the quantitative trait of median hepatic fat to interrogate the
clinical diagnosis phenotypes associated with hepatic fat (Appendix D, Figure S1). Hepatic fat
quantity was associated with increased risk for “Chronic liver disease and cirrhosis” (p=1.70E-45)
and “Other chronic nonalcoholic liver disease” (Phecode representing NAFLD; p=8.89E-42) at
phenome-wide significance. Hepatic fat also showed phenome-wide significant associations with
increased risk for cardiometabolic comorbidities such as “Type 2 diabetes” (p=9.42E-30),
“Obesity” (p=3.31E-18), and “Hypertension” (p=1.64E-13). Additionally, “Viral hepatitis” (p=1.17E05) and “Alcoholic liver damage” (p=3.50E-15) were associated with increased hepatic fat at
phenome-wide significance. Hepatic fat was also highly significantly associated with the
quantitative trait of BMI (p=1.94E-42; Appendix D, Table S1), consistent with the known
relationship between obesity and hepatic steatosis.
We also analyzed the association of hepatic fat with several clinical laboratory
quantitative traits (Appendix D, Table S1). We found that hepatic fat values were significantly
positively associated with serum ALT, AST, alkaline phosphatase, hemoglobin A1C, random
glucose, and random triglycerides, and significantly inversely associated with HDL cholesterol,
LDL cholesterol, and total cholesterol.
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Basic demographics
Total population, N

10283

Female, N (%)

4551 (44.3)

Median age, years

69

Genetically informed ancestry
AFR, N (%)

2814 (27.4)

AMR, N (%)

110 (1.1)

EAS, N (%)

103 (1.0)

EUR, N (%)

7096 (69.0)

SAS, N (%)

84 (0.8)

Phecodes
Chronic liver disease and cirrhosis, N (%)

1000 (9.7)

Other chronic nonalcoholic liver disease, N (%)

872 (8.5)

Type 2 Diabetes, N (%)

3018 (29.3)

Obesity, N (%)

2998 (29.2)

Essential hypertension, N (%)

6089 (59.2)

Alcoholic liver damage, N (%)

129 (1.3)

Viral hepatitis, N (%)

611 (5.9)

Portal hypertension, N (%)

135 (1.3)

Liver replaced by transplant, N (%)

260 (2.5)

Table 5.1. PMBB discovery cohort characteristics. Basic demographic characteristics and representative
Phecodes identified by PheWAS of median hepatic fat in PMBB. Each characteristic is labeled with count
data and percent prevalence where appropriate. Individuals were determined to be a case for a Phecode if
they had the corresponding ICD diagnosis on two or more dates, while controls consisted of individuals who
never had the ICD code. Individuals with an ICD diagnosis on only one date as well as those under control
exclusion criteria based on Phecode mapping protocols were not considered. AFR-African, AMR-Mixed
American, EAS-East Asian, EUR-European, SAS-South Asian
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5.4.2. Exome-wide analyses of single coding variants identify novel variants associated with
hepatic fat
We conducted a univariate exome-wide analysis of hepatic fat for all nonsynonymous
coding variants of sufficient frequency (MAF>0.1% in gnomAD) (Figure 5.1; Appendix D, Figure
S2). Among 120,315 total variants with at least 10 carriers, we identified 91 variants in 86 genes
with exome-wide significant (P<4.2E-07) or suggestive (P<9.9E-05) associations with hepatic fat
(Appendix D, Table S2). Among these included variants previously reported to be associated with
hepatic fat: PNPLA3 variants I148M, K434E, and S453I; TM6SF2 E167K; SAMM50 D110G;
NCAN P92S; PARVB W37R; and APOE4 (C130R). Additional positive control associations were
found below the significance threshold (Appendix D, Table S3), including GCKR L446P, MTARC1
T165A, and TM6SF2 L156P. 27 of the 91 single variants were African ancestry-specific variants
(African/European MAF ratio > 10 in gnomAD; Appendix D, Table S2).

Figure 5.1. Manhattan plot of single variant discovery in PMBB. Manhattan plot showing the results of
the exome-wide single variant discovery analysis in PMBB for coding variants of sufficient frequency
(MAF>0.1%, N≥10). The x axis represents the exome and is organized by chromosomal location. The

91

location of each single variant along the x axis corresponds to the genomic location for each variant
according to Genome Reference Consortium Human build 38 (GRCh38). The association of each single
variant with hepatic fat is plotted vertically above each variant. Each point is color-coded according to the
key for the type of analysis conducted, and the height of each point represents the –log10(p value) of the
association. Each variant is annotated with its corresponding gene name. The red line represents the
suggestive significance threshold at p=9.9E-05 to account for multiple hypothesis testing.

For replication, we tested the association of these 91 variants with liver proton density fat
fraction (PDFF) measurements derived from abdominal MRI scans in the UKB (Appendix D,
Table S4). Not only were the methods of hepatic fat quantitation different, but there were notable
differences in the distribution of hepatic fat between PMBB and UKB (Appendix D, Figure S3).
Furthermore, there was insufficient power in UKB for replication of the 27 African ancestryspecific variants, as 20 of 27 variants had N<5 in the cosmopolitan analyses. Despite this, in
addition to replicating a number of the previously known associations, we also replicated novel
associations of H600Y in FGD5 and a 6-bp deletion (S198_G199del) in CITED2 with hepatic fat.
To test whether rare predicted deleterious coding variants in the 86 unique genes
containing the 91 single variants were also associated with differences in hepatic fat, we
aggregated rare (MAF≤0.1% in gnomAD) pLOF variants into gene burdens for targeted
associations with hepatic fat in PMBB (Appendix D, Table S5). A burden of rare pLOF variants in
8 genes was significantly associated with hepatic fat, including genes with previously described
common variation associated in differences in hepatic fat such as PNPLA3 and PARVB, as well
as new findings like PTGR1. We also aggregated the combination of rare pLOF and rare
predicted deleterious missense (pDM) variants (REVEL≥0.5) per gene for targeted gene burden
association with hepatic fat in PMBB (Appendix D, Table S5). We found 11 additional genes
associated with differences in hepatic fat in PMBB by adding rare pDM variants to pLOFs.
Additionally, the associations for DISP2, PARVB, PTGR1, and QRFPR were strengthened or
remained significant with the addition of carriers for rare pDM variants. Of note, the combined
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CITED2 gene burden was nominally associated with increased median hepatic fat although
underpowered (N=3, beta=9.723, p=0.0276).
We also tested the burden of rare pLOFs in the 86 genes for association with hepatic fat
in UKB (Appendix D, Table S6) and found 3 concordant gene burdens, namely ADAM19, EXO5,
and SEMA3D. Additionally, the combined burden of rare pLOFs and rare pDM variants (Appendix
D, Table S6) revealed 3 additional significant genes, namely ADGRG5, GPS1, and NOX5. The
associations for EXO5 and SEMA3D were strengthened or remained nominally significant with
the addition of carriers for rare pDM variants.

5.4.3. A gene burden of rare pLOFs in LMF2 is associated with increased hepatic fat in PMBB
and UKB
We also performed an exome-wide rare pLOF gene burden analysis for association with
hepatic fat in PMBB. We aggregated rare (MAF≤0.1% in gnomAD) pLOFs per gene: among
4187 genes with at least 10 carriers for rare pLOFs who have hepatic fat quantifications available
(Appendix D, Figure S4), there were 26 genes that had exome-wide significant (P<1.2E-05) or
suggestive (P<9.9E-04) associations with hepatic fat (Figure 5.2; Appendix D, Table S7). For
these 26 genes, we attempted replication in UKB using a similar rare pLOF gene burden
approach. We found that the LMF2 pLOF gene burden had a significant association with hepatic
fat (beta=0.429, p=5.79E-03, N=5) and importantly in the same direction (increased) as we
observed in PMBB.
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Figure 5.2. Manhattan plot of rare pLOF gene burden discovery in PMBB. Manhattan plot showing the
results of the exome-wide gene burden discovery analysis in PMBB aggregating rare (MAF≤0.1%) predicted
loss-of-function (pLOF) variants per gene (N≥10). The x axis represents the exome and is organized by
chromosomal location. The location of each gene along the x axis corresponds to the genomic location for
each variant according to Genome Reference Consortium Human build 38 (GRCh38). The association of
each gene burden with hepatic fat is plotted vertically above each gene. Each point is color-coded according
to the key for the type of analysis conducted, and the height of each point represents the –log10(p value) of
the association. Each gene is annotated with its gene name. The red line represents the suggestive
significance threshold at p=9.9E-04 to account for multiple hypothesis testing.

We conducted an analysis of the association of the gene burden of rare pLOFs in LMF2
in PMBB (N=105 het carriers) with Phecodes in the “digestive” group (520 to 579.8). In addition to
a significant association with the NAFLD Phecode, the burden of pLOF variants in LMF2 had
significant associations with an array of biliary-related Phecodes such as “Cholangitis”, “Calculus
of bile duct”, “Cholelithiasis with acute cholecystitis”, and “Primary biliary cirrhosis” (Appendix D,
Table S8). Furthermore, the LMF2 pLOF gene burden was associated with increased serum
alkaline phosphatase, total cholesterol levels, and BMI (Appendix D, Table S9), as well as a trend
to an increase in triglycerides (beta=0.0474, p=0.0957). There were no significant associations
with HDL, LDL, ALT, or AST levels.
In a primary analysis of publicly available data, we found that Lmf2 expression was
significantly decreased in liver endothelial cells from cirrhotic livers of rats versus control
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(Appendix D, Figure S5), where cirrhosis was induced via inhalation of CCl4. Similarly, in a
hepatic steatosis mouse model due to hepatocyte-specific Sirt1 deficiency leading to impaired
PPARα signaling and decreased fatty acid beta-oxidation, Lmf2 liver expression was also
significantly decreased versus control (Appendix D, Figure S6).

5.5. Discussion
We present an exome-wide analysis of coding variants for association with hepatic fat
quantitated from abdominal CT scans via machine learning in a medical biobank. Our single
variant discovery analyses confirmed many previously described single variants associated with
hepatic fat or NAFLD risk which support the validity of our data and analysis pipeline, including
I148M, K434E, and S453I in PNPLA3,
SAMM50,
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P92S in NCAN,

T165A in MTARC1.

136

132

122,129

E167K and L156P in TM6SF2,

W37R in PARVB,
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C130R in APOE,
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D110G in

L446P in GCKR,
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and

We also conducted replication studies in UKB looking for consistent

directions of effect by linking exomes to hepatic fat based on liver PDFF extracted from
abdominal MRI scans, given the strong linear correlation between hepatic fat extracted from noncontrast CT and PDFF quantifications derived from MRI.
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Among our new significant single variants not previously associated with hepatic
steatosis in humans, we found that H600Y in FGD5 was associated with increased hepatic fat in
PMBB, which replicated in UKB. FGD5 encodes a protein which activates CDC42
expressed in the liver.
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and is also

CDC42 is a member of the Rho GTPase family and plays important

roles in the regulation of the cytoskeleton as well as cell proliferation, polarity, and transport.
Importantly, liver-specific knockout of Cdc42 in mice has been shown to lead to excessive hepatic
accumulation of lipids during liver regeneration after partial hepatectomy, likely due to impaired
cytoskeletal organization and intracellular trafficking in hepatocytes.
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Additionally, we found that

a 6-bp deletion in CITED2, a coactivator of HNF4α, was also associated with increased hepatic
95

fat in PMBB, which also replicated in UKB. A burden of rare predicted deleterious coding variants
in CITED2 was also associated with increased hepatic fat although underpowered. Cited2 has
been shown to be essential for mouse fetal liver development, and knockout of Cited2 in fetal
liver leads to disrupted sinusoidal architecture and accumulation of lipid droplets in the sinusoidal
space.
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There is a substantial gap of knowledge regarding the clinical implications of genetic
variants overrepresented among Africans due to the lack of ancestral diversity in populations
previously studied, especially regarding AFR-predominant genetic variants that modulate hepatic
fat.
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In the PMBB discovery cohort, 27.4% of individuals with WES linked to hepatic fat

quantifications were of African ancestry, and interestingly we identified 27 single variants
enriched among individuals of African ancestry which were significant in the PMBB discovery.
These variants represented a challenge for replication in UKB given that there are only 70
individuals who identified as having African, Caribbean or any other Black ethnic background in
the subset of individuals with MRI-derived hepatic fat linked to WES data in UKB. The previously
described AFR-predominant S453I variant in PNPLA3 and the new S198_G199del variant in
CITED2, among the more common of the 27 AFR-predominant variants, were able to be
replicated via cosmopolitan analyses in UKB. However, the rest of the AFR-predominant single
variants were in very low numbers in UKB and failed to replicate, likely due to lack of power, with
20 of 27 variants having N<5 and thus not even being included in replication studies. Our findings
suggest that larger experiments of this type in ethnically diverse cohorts are essential for
improving our understanding of the contribution of ancestry-specific genetic variation to the
regulation of intrahepatic fat.
For significant single variants, we also tested whether a gene burden of rare predicted
deleterious coding variants might also be associated with differences in intrahepatic fat. While
phenotype-first approaches to identifying pLOF carriers in genes nominated by GWAS loci for
hepatic fat among NAFLD cases have been difficult,
96
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our study used a genome-first approach to

identify pLOF carriers in PNPLA3, PARVB, and SAMM50 for associations with hepatic fat. We
report for the first time the associations of pLOFs in PNPLA3 and PARVB as well as pLOFs and
pDM variants in PARVB and SAMM50 with decreased hepatic fat in PMBB. The PNPLA3 pLOF
gene burden’s protective association is consistent with previous studies suggesting that
accumulation of PNPLA3 protein on lipid droplets causes hepatic steatosis, and that depletion of
the protein may be a potential strategy for therapeutic intervention.
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While additional functional

work would be needed to validate the associations for the PARVB and SAMM50 gene burdens,
our study suggests a protective role for haploinsufficiency in genes that were identified via
common variant associations with incompletely described functionalities with respect to gene
products.
The targeted gene burden associations for genes nominated by the single variant
discovery also shed light to genes with previously undescribed relationships to hepatic fat. Both
pLOFs and pDM variants in PTGR1 were associated with increased hepatic fat in PMBB. PTGR1
encodes an enzyme involved in the inactivation of the chemotactic factor leukotriene B4 and also
has its highest expression in the liver.
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insulin resistance in mouse hepatocytes,

Notably, leukotriene B4 has been shown to promote
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suggesting that haploinsufficiency of PTGR1 could

lead to unsuppressed activation of leukotriene B4 and thus development of insulin resistance in
the liver. Additionally, we found that pLOF variants in ADAM19 were associated with decreased
hepatic fat in UKB, consistent with the direction of effect of its respective single variant from
discovery (G660D), a pDM variant in ADAM19 (REVEL=0.683). Importantly, ADAM19 has been
suggested to be pro-obesogenic and enhance insulin resistance, and neutralization may be a
potential therapeutic approach to treating obesity and T2D.
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We also identified gene burdens of

pLOFs as well as pLOFs combined with pDM variants in QRFPR (GPR103), the receptor for
neuropeptide 26RFa (encoded by QRFP), as being associated with increased hepatic fat. 26RFa
and QRFPR work both in the hypothalamic nuclei to control feeding behavior as well as in the gut
and pancreatic islets.
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Specifically, 26RFa increases insulin sensitivity and prevents pancreatic
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beta cell death and apoptosis, and disruption leads to dysregulation of glucose homeostasis and
a deficit in insulin production by pancreatic islets.
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Taken together, our results suggest that

haploinsufficiency of QRFPR increases risk for hepatic steatosis through a mechanism of insulin
resistance.
We also report the first rare variant gene burden discovery analysis for exome-wide
gene-based associations with hepatic fat in a medical biobank. We identified a burden of rare
pLOF variants in LMF2 as being associated with increased hepatic fat in PMBB, which replicated
in UKB. Importantly, this association would have been missed in previous studies focusing on
common variants, and common variants in LMF2 were also not exome-wide significant in our
single variant discovery. LMF2 is a paralog of LMF1 and is the ancestral gene, and Lmf1
emerged in echinoderms after losing an internal segment of the DUF1222 domain and gaining a
new C-terminal tail with lipase maturation activity. While LMF2 does not have this C-terminus, it
may share a common ancestral cellular function with LMF1, possibly the maintenance of
endoplasmic reticulum homeostasis. While LMF2 lacks description in the literature, a study of
adolescents undergoing bariatric surgery with a high prevalence of NAFLD showed that LMF2
was one of the top down-regulated genes in the livers of those with non-alcoholic steatohepatitis
(NASH) versus not NAFLD control subjects.
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Similarly, hepatic Lmf2 expression was decreased

in cirrhotic rat livers and steatotic mouse livers versus controls.

127,128

While additional description

of the function of LMF2 is needed, our study suggests that LMF2 haploinsufficiency may
contribute to an increase in hepatic fat.
While many single variants successfully replicated in UKB following discovery analyses in
PMBB, we noticed a relative lack of significant findings when interrogating rare variant gene
burdens in UKB regarding replication of significant genes from the gene burden discovery as well
as targeted analyses of genes nominated by the single variant discovery. While the number of
samples with exome sequences linked to hepatic fat in UKB was comparable to PMBB, the
distribution of hepatic fat was substantially skewed toward lower values in UKB compared to the
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normal distribution in PMBB. This might be expected, given the UKB is a population-based
biobank that is widely recognized to have a “healthy volunteer selection bias”,
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and we have

previously described the relative lack of replication for rare variant gene burdens in UKB
compared to medical biobanks.
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Thus, our study suggests that additional experiments of this

type linking exome sequencing to imaging-derived hepatic fat quantifications in medical biobanks
are warranted to interrogate the impact of rare variation on differences in hepatic fat.
We recognize that while CT imaging provides the opportunity to quantify hepatic fat
through rapid and scalable imaging, there are some limitations. In particular, the presence of iron,
copper, glycogen, fibrosis, or edema may confound attenuation values and lead to errors in
hepatic fat quantification.
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However, by conducting replication studies in UKB by interrogating

PDFF derived from MRI, we suggest that replicated signals are less likely to be confounded by
these factors, given that PDFF is a more accurate measure with less confounding variables.
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Thus, while the magnitude of effect size for genetic associations may differ between CT-derived
and MRI-derived hepatic fat quantifications, we suggest that there is value in interrogating
multiple imaging modalities for increased specificity.
In conclusion, by linking exome sequences to hepatic fat quantifications in a medical
biobank, our study not only adds to the breadth of knowledge regarding single coding variants
and their associations with hepatic fat and NAFLD risk through our exome-wide single variant
discovery analyses, but also provides gene-based associations which support the genes
nominated by single variants and suggests mechanisms of haploinsufficiency by which these
genes may affect the regulation of intrahepatic fat. Furthermore, our study demonstrates the
feasibility and value of aggregating rare predicted deleterious coding variants into gene burdens
on an exome-wide scale for association with hepatic fat quantifications for the discovery of new
genes which may regulate intrahepatic fat and confer risk for or protect from NAFLD. We suggest
that much larger experiments of this type which link genetic sequencing to quantitated hepatic fat

99

will lead to many new insights into genes which regulate hepatic fat and modulate risk for NAFLD
and other metabolic comorbidities.
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CHAPTER 6. Conclusions and future directions

The analyses of this dissertation clearly demonstrate the value of using a genome-first
approach to interrogating rare coding variation to describe how loss of gene function may impact
human disease. By linking whole-exome sequences to electronic health records (EHR) in the
Penn Medicine BioBank (PMBB), this dissertation first determined key methodologies for a
genome-first approach to selecting rare variants for gene burden association tests to establish a
platform by which the upcoming analyses could apply these approaches to provide new insights
into the role of many genes in human biology and phenotypes. Importantly, the significance of
assessing both predicted loss-of-function (pLOF) and predicted deleterious missense (pDM)
variants for gene burden testing was emphasized through the explorations of variant selection
methods. Then, by applying these approaches, the analyses of this dissertation demonstrated the
utility of a genome-first approach to conducting gene burden association tests to describe
expected and unsuspected clinical implications of loss-of-function in both well-described and
novel genes. More specifically, Chapters 2 and 3 took advantage of known ‘positive control’ genephenotype associations to assess the performance of rare variant selection methods for gene
burden association testing, and in doing so also revealed novel pleiotropic relationships for LMNA
as well as major gene-specific differences in ideal gene burdening approaches for two genes both
intimately tied to the pathogenesis of the same disease, namely MYBPC3 and MYH7. Then,
Chapters 4 and 5 demonstrated how application of a genome-first approach to rare variant gene
burden testing on an exome-wide scale allowed for identification of several novel gene-phenotype
relationships.
While PMBB is a healthcare-based population with enrichment for rare diseases which
allowed for the potential to substantially gain new insights into the biology of human phenotypes
and diseases in this dissertation, a major takeaway and suggestion from these analyses is that
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application of this genome-first approach to even larger numbers of individuals are likely to be
highly informative, providing the statistical power required to uncover unexplored relationships
between rare genetic variation and human disease phenotypes. Already there are efforts
underway to conduct rare variant-based exome-by-phenome-wide association studies in larger
populations, as shown by studies in the first 45K+ individuals with exome sequencing linked to
disease phenotypes in the UK Biobank (UKB)
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as well as updated analyses in the larger,

more recent ~200K individuals with exome sequencing in UKB.
widely recognized to have a ‘healthy volunteer selection bias’
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However, given that the UKB is

as we also demonstrated through

comparisons of disease prevalence between multiple medical biobanks versus UKB in Chapter 4,
there are clearly many more opportunities ahead within the realm of investigating the clinical
implications of rare coding variation in sicker populations such as healthcare-based medical
biobanks to uncover additional insights into novel gene biology and function, as we still do not
know how loss-of-function in most human genes impact disease.
In addition to being enriched for disease, PMBB has the advantage of being ancestrally
diverse. The analyses of this dissertation were empowered to conduct genetic association studies
in both African and European ancestry due to the relatively high prevalence of individuals of
African ancestry in PMBB (19.9% to 27.4% across Chapters 2-5). There has been a significant
gap of knowledge regarding the clinical implications of genetic variants overrepresented among
individuals of Africans ancestry due to previous genetic association studies lacking ancestral
diversity in the populations that have been analyzed, usually being limited to individuals of
European ancestry.
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Importantly, this dissertation addressed this gap of knowledge by not only

including individuals of African ancestry for all analyses performed but also identifying several
African ancestry-specific single variants which are robustly associated with diseases and traits.
For example, Chapter 4 identified 16 rare predicted deleterious single variants which are African
ancestry-specific and that replicated associations with the same disease in which a pLOF gene
burden was associated in the exome-by-phenome-wide discovery. Additionally, Chapter 5
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identified 27 single variants enriched among individuals of African ancestry which were
significantly associated with differences in intrahepatic fat in the PMBB discovery analyses. As
might be expected, most of these African-specific variants neither exist in the GWAS catalog nor
have been previously mentioned in the published literature. These analyses suggest that it is
imperative for future studies in this field to address the need for more diversity in genomic
experiments of this type by analyzing ethnically diverse cohorts to improve our understanding of
the contribution of previously missed ancestry-specific variation to human disease.
In the 2020 National Human Genome Research Institute’s (NHGRI) Strategic Vision, the
NHGRI made ten bold predictions for human genomics that might come true by 2030,
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many of

which are relevant to future directions for these types of studies. Prediction #2 states that “the
biological function(s) of every human gene will be known,” which is a major goal and impetus for
conducting larger studies of this type in diverse, sick populations. One obvious place to start is for
all Mendelian genes with known phenotype associations but remaining enigmatic gene biology
and clinical implications. Application of a genome-first approach to rare variants like the analyses
performed in Chapters 2-4 for all such Mendelian genes could cover significant distance toward
reaching that goal. For example, Chapter 4 confirmed that a gene burden of rare pLOFs in CFTR
was significantly associated with cystic fibrosis (CF), a recessive Mendelian condition caused by
biallelic variants in CFTR. But in addition, we found that the CFTR pLOF gene burden was also
significantly associated with bronchiectasis independent of a CF diagnosis and occurred in
individuals without a second CFTR variant, strengthening previous suggestions of predisposition
to bronchiectasis due to haploinsufficiency of CFTR.
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These kinds of analyses of Mendelian and

clinically actionable genes could also help clarify the interpretation and relevance of genomic
variants encountered in the clinical setting, essentially heading toward achieving prediction #7 of
“rendering the diagnostic designation ‘variant of uncertain significance (VUS’ obsolete.”
Furthermore, such studies could aid in the translation of important findings from genomic
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research into the clinic such that the regular use of genomic information will become mainstream
in all clinical settings.
The analyses of this dissertation demonstrated how a genome-first approach to
interrogating rare loss-of-function variants can link haploinsufficiency in a gene to conferment of
risk for or protection from disease. However, the relative scarcity of homozygotes or compound
heterozygotes for rare loss-of-function variants in these analyses represents a major limitation of
the genome-first approach in outbred populations like PMBB. This relative scarcity essentially
mandated the rare variant analyses of this dissertation to explore gene-phenotype associations
based on haploinsufficiency. However, other studies focusing on consanguineous, founder, or
bottleneck populations such as the Pakistan Risk of Myocardial Infarction Study (PROMIS)
FinnGen
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and

are likely to be more successful in identifying homozygotes for ascertaining

phenotypes that are ‘recessive’ as are many linked to Mendelian genes, though statistical power
for interrogation of rare disease phenotypes will continue to be a challenge.
This dissertation also demonstrated how quantitative imaging-derived phenotypes (IDP)
that are correlated with disease risk can provide information beyond that captured in binary EHR
diagnoses. For example, Chapters 2 and 3 used echocardiographic data to show that carriers of
predicted deleterious variants in LMNA, MYBPC3, and MYH7 have abnormal cardiac
morphologies which may not necessarily pass the threshold for clinical diagnosis of disease but
certainly warrant clinical follow-up for preventive actions. As another example, Chapter 5
demonstrated how exome-wide analyses of hepatic fat quantifications, which are correlated with
risk for non-alcoholic fatty liver disease (NAFLD) as well as various other comorbidities such as
type 2 diabetes and cardiovascular disease, shed light to new genetic variants which are
associated with differences in hepatic fat but may not be captured when analyzing binary NAFLD
diagnosis rates. Another advantage of analyzing the genetic architecture of quantitative IDPs,
which was not specifically assessed in this dissertation, is the potential to interrogate directions of
effect. Future studies which prove that loss-of-function variants in a certain gene lead to one
104

direction of effect for a given IDP and subsequently discover another variant in the same gene
that is robustly associated with the opposite direction of effect for the same IDP could identify
novel gain-of-function variants.
Importantly, this concept could extend to genomic analyses of any clinical quantitative
phenotype, which leads to another major future direction for analyzing rare variation. If one could
identify that loss-of-function in a gene leads to protection from disease, this could be directly
translated to curative therapies. For example, gain-of-function variants in PCSK9 were discovered
to be associated with very high circulating LDL cholesterol levels, which led to the subsequent
finding through targeted sequencing of individuals with very low circulating LDL levels that lossof-function variants in PCSK9 lower LDL.
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This finding ultimately led to the development of

PCSK9 inhibitors, which are monoclonal antibodies that antagonize PCSK9 protein and lead to
increased LDL receptors and thus therapeutically decreased circulating LDL cholesterol levels.
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Additionally, identification of protective gain-of-function variation could also lead to development
of curative therapies, although identification of such variants as well as therapeutic translation
through genomic modifications may be more difficult. Analyzing quantitative traits such as IDPs
may allow such discovery of protective gain-of-function variants to be more feasible due to the
ability to compare directions of effect for the associations of different coding variants in the same
gene with a single quantitative phenotype. For example, knowing that loss-of-function variants in
APOA5 lead to hypertriglyceridemia,
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one could systematically search for single coding variants

in APOA5 that are associated with decreased serum triglyceride levels to uncover potentially
novel gain-of-function variants which are protective for cardiovascular disease. Thus, systematic
analyses of quantitative traits in large biobanks could help in identifying novel gain-of-function
variants throughout the human genome. Furthermore, recent advances in in silico predictions of
three-dimensional protein folding may accelerate the identification of gain-of-function variants,
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which could one day allow for genome-first approaches to exome-wide analyses of the clinical
implications of human gain-of-function variants. This may make NHGRI’s bold prediction #10 for
105

2030 feasible—that “breakthrough discoveries will lead to curative therapies involving genomic
modifications for dozens of genetic diseases.”
The success in identifying compelling findings based on the limited number of individuals
included in the analyses of this dissertation (~11K to ~44K in PMBB) is promising, in that there is
hope that the rate of new discovery for gene-phenotype relationships will accelerate over the next
decade as the approaches detailed in this dissertation are applied to much larger populations and
thus potentiate many new insights into gene biology and function through increased statistical
power. As our understanding of the biological and clinical relevance of rare variation becomes
more complete, genomic testing becomes more routine in the clinical setting, and a better
understanding of the genomic architecture of human disease becomes translated to curative and
even preventive therapeutics, human health disparities and outcomes are likely to improve with
the hope that these future services are equitably offered, as it should be a human right to
appropriately act upon the genome one is innately inherited with for the benefit of one’s health.
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